BSE Healthcare

FORTIS HEALTHCARE: CO APPROVED RAISING OF FUNDS WORTH 1500 CR RUPEES VIA ISSUE OF NCDS

SUN PHARMA: BOARD MEETING ON OCTOBER 28 TO CONSIDER Q2 RESULTS

ALEMBIC PHARMA: SUCCESSFULLY COMPLETES USFDA INSPECTION OF ONCOLOGY FORMULATION FACILITY AT PANELAV WITH NO OBSERVATIONS

DR REDDYS LAB: CO SAYS DCGI GIVEN NOD TO COMMENCE PHASE 2 PART OF TRIAL

DR. REDDY’S LABS: CO SUBSIDIARY AURIGENE ONCOLOGY LTD ANNOUNCES PROMISING RESULTS OF PHASE 1 STUDY FOR INDIA’S FIRST TRIAL FOR NOVEL AUTOLOGOUS CAR-T CELL THERAPY FOR MULTIPLE MYELOMA

BIOCON: BIOCON BIOLOGICS’ COMMISSIONED REPORT HIGHLIGHTS PATHWAYS TO INCREASE ADOPTION OF BIOSIMILARS IN LMICS

MAX HEALTHCARE INSTITUTE LTD: RS. 95.05 CRORES NSE BLOCK TRADE; FOR ~ 1002688 SHARES, AT RS. 948.00

MAX HEALTHCARE INSTITUTE LTD: RS. 74.32 CRORES NSE BLOCK TRADE; FOR ~ 803149 SHARES, AT RS. 925.40

APOLLO HOSPITALS ENTERPRISE LTD: Rs. 26.20 Crores NSE Block Trade; for ~ 38529 Shares, at Rs. 6800.00

WOCKHARDT: CO ANNOUNCES ANOTHER BREAKTHROUGH ANTI-BIOTIC: ONCE-A-DAY B-LACTAM ENHANCER WCK 6777 (ERTAPENEM/ZIBDEBACTAM) WITH UNIQUE OUT-PATIENT TREATMENT ADVANTAGE GRANTED FAST TRACK DESIGNATED BY US FDA AND SUCCESSFULLY COMPLETES PHASE I STUDY CONDUCTED BY NATIONAL INSTITUTES OF HEALTH, US

WOCKHARDT: CO ANNOUNCES ANOTHER BREAKTHROUGH ANTI-BIOTIC: ONCE-A-DAY B-LACTAM ENHANCER WCK 6777 (ERTAPENEM/ZIBDEBACTAM) WITH UNIQUE OUT-PATIENT TREATMENT ADVANTAGE GRANTED FAST TRACK DESIGNATED BY US FDA AND SUCCESSFULLY COMPLETES PHASE I STUDY CONDUCTED BY NATIONAL INSTITUTES OF HEALTH, US

NATCO PHARMA: CO AND MYLAN ARE PARTNERED ON THE DEVELOPMENT OF GENERIC OZEMPIC PRODUCTS. THE TERMS OF THE SETTLEMENT ARE CONFIDENTIAL

NATCO PHARMA: CO ANNOUNCES THAT MYLAN PHARMA INC. AND NOVO NORDISK HAVE REACHED A SETTLEMENT OF THE U.S. PATENT LITIGATION RELATED TO GENERIC OZEMPIC (SEMAGLUTIDE)

LUPIN: U.S. FDA HAS COMPLETED A PRE-APPROVAL INSPECTION OF CO BIOTECH FACILITY LOCATED IN PUNE WITH 5 OBSERVATION

FORTIS HEALTHCARE: BOARD MEETING ON OCT 9 TO CONSIDER ISSUE OF NON- CONVERTIBLE DEBENTURES

JUBILANT PHARMOVA: CO SAYS UNIT JBIRSPL TO ACQUIRE 80% EQUITY CAPITAL IN JASMIN FOR UPTO 4.4M EURO -- JASMIN TO ACQUIRE PIERRE FABRE’S R&D CENTRE AT SAINT JULIEN, FRANCE; ENTITY BEING ACQUIRED BELONGS TO DRUG DISCOVERY FOR BIOLOGICS AND ADCS

SYNGENE INTERNATIONAL: BOARD MEETING ON OCT 23 TO CONSIDER Q2 RESULTS

METROPOLIS HEALTH: CO SAYS Q2FY25 REVENUES GREW BY 13% ON (YOY) BASIS -- CO SAYS B2C REVENUES GREW AT 20% ON A (YOY) BASIS ON ACCOUNT OF INDUSTRY-LEADING TESTING CAPABILITIES AND STRONG BRAND APPEAL AMONG END CONSUMERS

MAX HEALTHCARE INSTITUTE LTD: RS. 62.14 CRORES NSE BLOCK TRADE; FOR ~ 664442 SHARES, AT RS. 935.25

INDOCO REMEDIES: CO SAYS CETIRIZINE IS USED FOR RELIEF OF SYMPTOMS OF HAY FEVER AND OTHER ALLERGIC CONDITIONS

INDOCO REMEDIES: CO RECEIVES FINAL ANDA APPROVAL FROM THE USFDA FOR CETIRIZINE HYDROCHLORIDE TABLETS USP, 10 MG (OTC)

AARTI DRUGS: CO SAYS RECEIPT OF GMP CERTIFICATE FROM UK-MHRA FOR MANUFACTURING FACILITY OF UNIT

BIOCON: BOARD MEETING ON OCT 30 TO CONSIDER Q2 RESULTS

SHILPA MEDICARE: CO UNIT GOT CERTIFICATE OF SUITABILITY FROM EDQM FOR API, DESMOPRESSIN

SUVEN LIFE SCIENCES: CO TO PRESENT POSITIVE RESULTS FROM PHASE-2A PROOF-OF-CONCEPT STUDY OF ROPANICANT (SUVN-911) AND UPDATES ON INNOVATION PIPELINE ASSETS AT NEUROSCIENCE 2024, CHICAGO, USA

SUVEN LIFE SCIENCES: CO TO PRESENT POSITIVE RESULTS FROM PHASE-2A PROOF-OF-CONCEPT STUDY OF ROPANICANT (SUVN-911) AND UPDATES ON INNOVATION PIPELINE ASSETS AT NEUROSCIENCE 2024, CHICAGO, USA

APOLLO HOSPITALS ENTERPRISE LTD: Rs. 49.83 Crores NSE Block Trade; for ~ 70343 Shares, at Rs. 7083.90

ERIS LIFESCIENCES LTD: RS. 270.76 CRORES NSE BLOCK TRADE; FOR ~ 2004438 SHARES, AT RS. 1350.80

BIOCON: BIOCON BIOLOGICS REFINANCES USD 1.1B (RUPEES 93,468M) LONG TERM DEBT THROUGH USD BONDS AND NEW SYNDICATED FACILITY

ALEMBIC PHARMA: CO ANNOUNCES USFDA FINAL APPROVAL FOR LAMOTRIGINE EXTENDEDRELEASE TABLETS USP, 200 MG, 250 MG, AND 300 MG -- THIS TABLES HAS US SALES OF USD 163M

DR. REDDY’S LAB: CO SIGNS VOLUNTARY LICENSING AGREEMENT WITH GILEAD SCIENCES TO MANUFACTURE AND COMMERCIALISE LENACAPAVIR IN INDIA AND OTHER COUNTRIES

ZYDUS LIFESCIENCES: ZYDUS RECEIVES TENTATIVE APPROVAL FROM USFDA FOR ENZALUTAMIDE TABLETS, 40 MG AND 80 MG -- ENZALUTAMIDE TABLETS, 40 MG AND 80 MG HAD ANNUAL SALES OF USD 1417.2M IN THE UNITED STATES (IQVIA MAT JULY 2024)

SMS PHARMA: CO RECEIVES EDQM CERTIFICATION TO SUPPLY IBUPROFEN IN EUROPE

MANKIND PHARMA: INDIA CCI APPROVES ACQUISITION OF BHARAT SERUMS AND VACCINES LTD BY MANKIND PHARMA

JB CHEMICALS: CO SAYS INVESTMENT REQUIRED FOR IV MANUFACTURING EXPANSION AT 494.9M RUPEES -- INVESTMENT REQUIRED FOR MANUFACTURING LINE AT 215.5M RUPEES

JB CHEMICALS: CO APPROVED CAPACITY ADDITION TO IV MANUFACTURING FACILITY AT PANOLI -- CO SAYS ESTABLISHMENT OF DEDICATED MANUFACTURING LINE FOR POVIDONE/IODINE LIQUID, OINTMENT

AUROBINDO PHARMA: CO RECEIVES USFDA APPROVAL FOR CEPHALEXIN TABLETS USP, 250 MG AND 500 MG

GLOBAL HEALTH LTD: RS. 60.88 CRORES NSE BLOCK TRADE; FOR ~ 611907 SHARES, AT RS. 994.95

ZYDUS LIFE: CO RECEIVES USFDA EIR REPORT FOR TRANSDERMAL PATCH MANUFACTURING FACILITY IN AHMEDABAD, CLASSIFIED AS VAI

SUN PHARMA: CO SAYS THE TWO PARTNER COMPANIES WILL SHARE POST-COMMERCIALIZATION ECONOMICS IN ABOUT 45(PHILOGEN):55(SUN PHARMA) RATIO

SUN PHARMA: CO SAYS THE TWO PARTNER COS WILL SHARE POST-COMMERCIALIZATION ECONOMICS IN ABOUT 45 (PHILOGEN): 55 (SUN PHARMA) RATIO

SUN PHARMA: CO SAYS FIBROMUN, AN INNOVATIVE ANTI-CANCER IMMUNOTHERAPY, IS BEING INVESTIGATED IN REGISTRATION TRIALS BY PHILOGEN FOR THE TREATMENT OF SOFT TISSUE SARCOMA AND GLIOBLASTOMA

SUN PHARMA: CO AND PHILOGEN ENTER INTO A GLOBAL EXCLUSIVE COMMERCIALIZATION, LICENSE, AND SUPPLY AGREEMENT FOR COMMERCIALIZING THE SPECIALTY PRODUCT FIBROMUN

KRSNAA DIAGNOSTICS: CO AND MEDIKABAZAAR PARTNER FOR AN UNMATCHED STRATEGIC COLLABORATION TO REVOLUTIONIZE ADVANCED DIAGNOSTICS IN INDIA WITH A PARTNERSHIP WORTH RUPEES 300+ CR, TO MAKE HEALTHCARE MORE ACCESSIBLE FOR ALL

MANKIND PHARMA: CO BOARD APPROVES UP TO RS 10,000 CRORE FUNDRAISING PLAN - MONEYCONTROL

UNICHEM LABORATORIES: PURCHASE FOR $2.7M -- UNIT TO BUY USA GENERICS FORMULATIONS MARKETING/DISTRIBUTION BUSINESS OF BAYSHORE USA; UNITS DEAL FOR $10M

UNICHEM LABORATORIES: CO APPROVED ENTERING INTO AGREEMENTS WITH BAYSHORE PHARMACEUTICALS LLC 30 -- PURCHASE OF RIGHTS, TITLE, INTEREST IN PRODUCT, GOODWILL ASSOCIATED WITH 9 ANDAS OF BAYSHORE USA

PIRAMAL PHARMA SOLUTIONS: CO ANNOUNCES $80M EXPANSION PLAN FOR STERILE INJECTABLES FACILITY IN LEXINGTON, KENTUCKY

KRSNAA DIAGNOSTICS: CO TO ENTER INTO A STRATEGIC COLLABORATION WITH BOSTON IVY HEALTHCARE SOLUTION (P) LIMITED (ALSO KNOWN AS MEDIKABAZAAR) AND UNITED IMAGING HEALTHCARE

AUROBINDO PHARMA: CO SAYS COMPLETION OF US FDA INSPECTION AT UNIT II OF APITORIA PHARMA -- INSPECTION CLOSED WITH 10 OBSERVATIONS

DR REDDYS LAB: CO MADE INVESTMENT OF USD 620M IN DR. REDDY’S LABORATORIES SA, SWITZERLAND

ALEMBIC PHARMACEUTICALS: CO ANNOUNCES USFDA FINAL APPROVAL FOR PALIPERIDONE EXTENDED RELEASE TABLETS, 1.5 MG, 3 MG, 6 MG, AND 9 MG -- PALIPERIDONE EXTENDED-RELEASE TABLETS, 1.5 MG, 3 MG, 6 MG, AND 9 MG HAVE AN ESTIMATED MARKET SIZE OF US$48M FOR TWELVE MONTHS ENDING JUNE 2024 ACCORDING TO IQVIA

MAX HEALTHCARE INSTITUTE LTD: RS. 79.87 CRORES NSE BLOCK TRADE; FOR ~ 802182 SHARES, AT RS. 995.65

ALKEM LABS: CO SAYS ALL PRODUCTS MANUFACTURED AT OUR SITES FOLLOW CURRENT GOOD MANUFACTURING PRACTICES -- SAMPLES OF PRODUCTS MENTIONED IN CDSCO LIST ARE SPURIOUS, NOT MANUFACTURED BY ALKEM

ALKEM LABS: CO DENIES CLAIMS OF PAN-D, CLAVAM 625 BATCHES BEING NOT-OF-STANDARD QUALITY

ALEMBIC PHARMACEUTICALS: CO RECEIVES USFDA FINAL APPROVAL FOR PALIPERIDONE EXTENDEDRELEASE TABLETS, 1.5 MG, 3 MG, 6 MG, AND 9 MG. -- US SALES OF USD 48M

GLAND PHARMA LTD: RS. 100.52 CRORES NSE BLOCK TRADE; FOR ~ 564726 SHARES, AT RS. 1780.00

YATHARTH HOSPITAL: NOIDA & GREATER NOIDA HOSPITAL SHOULD TOUCH OCCUPANCY OF 70-75% - CNBCTV18

ZYDUS LIFE: CO AND CSIR-CENTRAL DRUG RESEARCH INSTITUTE LUCKNOW TO DEVELOP BEST-IN-CLASS DRUG FOR CHRONIC KIDNEY DISEASE INDUCED OSTEOPOROSIS

LUPIN LTD: RS. 67.70 CRORES NSE BLOCK TRADE; FOR ~ 309414 SHARES, AT RS. 2188.15

MAX HEALTHCARE INSTITUTE LTD: Rs. 25.14 Crores NSE Block Trade; for ~ 254375 Shares, at Rs. 988.50

MAX HEALTHCARE: CO ACQUIRES 63.65% STAKE IN JAYPEE HEALTHCARE FOR RUPEES 398 CR IN STRATEGIC DEAL WITH LAKSHDEEP GROUP

TORRENT PHARMA: CO INCORPORATED UNIT NAMELY TORRENT PHARMACEUTICALS CHILE SPA -- ENTITY BEING ACQUIRED BELONGS TO PHARMACEUTICALS SECTOR

SEQUENT SCIENTIFIC: CO, VIYASH LIFE SCIENCES EXPLORE MERGER WORTH RS 7000-8000 CR - ET

TORRENT PHARMA: CO REFUTES CLAIMS OF SHELCAL 500 ALLEGEDLY FAILING CDSCO QUALITY TEST

SUN PHARMA: CO SAYS STUDIES ALSO CONFIRM DOSE OPTIMIZATION, WITH RESULTS DEMONSTRATING GREATER RESPONSE WITH 8 MG TABLETS TWICE-DAILY AS COMPARED TO HIGHER ONCE-DAILY DOSING

SUN PHARMA: CO PRESENTS NEW CLINICAL EFFICACY AND SAFETY DATA IN SEVERE DERMATOLOGICAL CONDITIONS AT THE 2024 EADV CONGRESS -- NEW DATA DEMONSTRATE IMPROVED HAIR SATISFACTION IN MORE THAN 95% OF PATIENTS TAKING DEURUXOLITINIB AND CLINICALLY MEANINGFUL IMPROVEMENTS IN DEPRESSION AND ANXIETY FROM BASELINE TO WEEK 24

JUBILANT PHARMOVA: CO ANNOUNCES COMPLETION OF USFDA AUDIT OF ALLERGY IMMUNOTHERAPY FACILITY & CONTRACT MANUFACTURING FACILITY LOCATED AT SPOKANE, WASHINGTON (USA) -- CO SAYS THE INSPECTION CONCLUDED WITH NO OBSERVATIONS

BIOCON: CO PARTNERS WITH TABUK PHARMACEUTICALS TO COMMERCIALIZE ITS GLUCAGON-LIKE PEPTIDE-1 (GLP -1) PRODUCTS IN THE MIDDLE EAST REGION

KRSNAA DIAGNOSTICS: CO GOT LOI TO COMMISSION RADIOLOGY SERVICES

MAX HEALTHCARE INSTITUTE LTD: Rs. 32.24 Crores NSE Block Trade; for ~ 324349 Shares, at Rs. 994.10

KRSNAA DIAGNOSTICS: CO SAYS WITH THIS PARTNERSHIP CANCER & CARDIAC PATIENTS WILL BE ABLE TO AVAIL COMPLETE SUITE OF DIAGNOSTIC SERVICES 24X7 UNDER ONE ROOF

KRSNAA DIAGNOSTICS: CO ACQUIRES STRATEGIC STAKE IN INDIA’S FIRST PPP DEDICATED FOR CANCER & CARDIAC CARE HOSPITALS

SYNGENE INTERNATIONAL LTD: RS. 61.58 CRORES NSE BLOCK TRADE; FOR ~ 703898 SHARES, AT RS. 874.90

FORTIS: IHH SAYS WILL REVISE OPEN OFFER PRICE HIGHER ONCE NOD COMES IN WILL INCREASE OUR STAKE,EITHER VIA OPEN OFFER OR BY CREEPING ACQUISITION

MAX HEALTHCARE INSTITUTE LTD: RS. 51.85 CRORES NSE BLOCK TRADE; FOR ~ 526465 SHARES, AT RS. 984.80

APOLLO HOSPITALS ENTERPRISE LTD: Rs. 30.39 Crores NSE Block Trade; for ~ 42575 Shares, at Rs. 7137.75

ALKEM LABS: CENTRAL DRUGS STANDARD CONTROL ORGANISATION, HAS FLAGGED 53 DRUG SAMPLES FOR FAILING TO MEET QUALITY STANDARDS - ET NOW

KRSNAA DIAGNOSTICS: CO APPROVED INVESTMENT IN APULKI HEALTHCARE -- CO SHALL ACQUIRE 23.53% OF STAKE IN APULKI -- ENTITY BEING ACQUIRED IS ENGAGED IN ESTABLISHING, OPERATING AND MAINTAINING HOSPITALS, FOCUSING ON ONCOLOGY AND CARDIOLOGY.

ALKEM LAB: ANTACID PAN D, PARACETAMOL, GLIMEPIRIDE AMONG OVER 50 DRUGS FAIL QUALITY TEST - THE NEW INDIAN EXPRESS

AARTI DRUGS: CO RECEIVED 7 INSPECTIONAL OBSERVATIONS IN FORM 483 FROM US FDA

AARTI DRUGS: US FDA INSPECTION WAS AT API MANUFACTURING FACILITY AT TARAPUR -- CO RECEIVED 7 INSPECTIONAL OBSERVATIONS IN FORM 483 FROM US FDA

CIPLA: CO PURCHASE OF 6.9124% EQUITY INTEREST OF JIANGSU XIDI PHARMACEUTICALS HELD IN CIPLA (JIANGSU) -- DEAL FOR RMB 35.8M

MAX HEALTHCARE INSTITUTE LTD: RS. 65.67 CRORES NSE BLOCK TRADE; FOR ~ 659945 SHARES, AT RS. 995.10

GLAND PHARMA LTD: Rs. 36.01 Crores NSE Block Trade; for ~ 194237 Shares, at Rs. 1853.75

MAX HEALTHCARE INSTITUTE LTD: RS. 50.00 CRORES NSE BLOCK TRADE; FOR ~ 502871 SHARES, AT RS. 994.35

JB CHEMICALS: CO FACES A DISAGREEMENT REGARDING THE VALUATION OF KKRS 54% EQUITY STAKE IN THE COMPANY, INDICATING POTENTIAL HURDLES IN NEGOTIATIONS- ETNOW

BIOCON: CO SAYS BIOCON BIOLOGICS ANNOUNCES NEW DERMATOLOGY DATA TO BE PRESENTED AT EADV CONGRESS 2024 -- A PHASE 3 STUDY SUPPORTS THE INTERCHANGEABILITY OF ADALIMUMAB AND ADALIMUMAB-FKJP, AND DEMONSTRATES BIOSIMILARITY BETWEEN BMAB 1200 AND USTEKINUMAB IN PATIENTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS.

GLAND PHARMA LTD: RS. 117.14 CRORES NSE BLOCK TRADE; FOR ~ 628093 SHARES, AT RS. 1865.00

GLAND PHARMA LTD: RS. 117.14 CRORES NSE BLOCK TRADE; FOR ~ 628093 SHARES, AT RS. 1865.00

GLAND PHARMA LTD: RS. 117.14 CRORES NSE BLOCK TRADE; FOR ~ 628093 SHARES, AT RS. 1865.00

LUPIN LTD: RS. 68.26 CRORES NSE BLOCK TRADE; FOR ~ 307212 SHARES, AT RS. 2222.05

GLOBAL HEALTH LTD: Rs. 22.01 Crores NSE Block Trade; for ~ 202920 Shares, at Rs. 1084.80

ASTRAZENECA PHARMA: CO HAS RECEIVED PERMISSION TO IMPORT FOR SALE AND DISTRIBUTION OF DURVALUMAB 120 MG/2.4 ML AND 500 MG/10 ML SOLUTION FOR INFUSION (IMFINZI) FROM THE CENTRAL DRUGS STANDARD CONTROL ORGANISATION

IPCA LABS: BOARD MEETING SCHEDULED FOR SEPTEMBER 30 TO INTEGRATION AND CONSOLIDATION OF THE GENERICS FORMULATIONS BUSINESS IN THE US MARKET

GLOBAL HEALTH LTD: Rs. 26.05 Crores NSE Block Trade; for ~ 232039 Shares, at Rs. 1122.85

UNICHEM LABS: CO TO CONSIDER CONSOLIDATION OF GENERICS FORMULATIONS BUSINESS IN US MARKET

BIOCON: CO SAYS US FDA COMPLETES INSPECTION OF BENGALURU API FACILITY WITH THREE OBSERVATIONS, NO BUSINESS IMPACT EXPECTED

ASTER DM HEALTHCARE: CO UNIT HAS ENTERED INTO LEASE AGREEMENT WITH APARNA CONSTRUCTIONS AND ESTATES PVT LTD FOR SETTING UP NEW ASTER WOMAN AND CHILDREN HOSPITAL IN HYDERABAD

GLENMARK PHARMA: CO SAYS US FDA FINDS NO OBSERVATIONS FOR MFG FACILITY IN AURANGABAD

TORRENT PHARMA: CO ISSUED COMMERCIAL PAPERS FOR 2B RUPEES

ASTRAZENECA PHARMA: CO WILL LAUNCH TREMELIMUMAB (IMJUDO) IN OCTOBER 2024 -- TREMELIMUMAB (IMJUDO) IN COMBINATION WITH DURVALUMAB (IMFINZI) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC)

MANKIND PHARMA: CO BOARD APPROVES FUND RAISE WORTH 100B RUPEES VIA ISSUE OF NON-CONVERTIBLE DEBENTURES AND COMMERCIAL PAPERS

GLENMARK PHARMA: CO SAYS U.S. FDA HAS ISSUED FORM 483 WITH ZERO OBSERVATIONS AFTER AN INSPECTION AT THE CO’S FORMULATION MANUFACTURING FACILITY BASED OUT OF CHHATRAPATI SAMBHAJI NAGAR (AURANGABAD), BETWEEN SEPT 09 AND SEPT 20

DR. REDDY’S LABORATORIES: CO SAYS INSPECTION WAS CONDUCTED FROM 16TH SEPT TO 20TH SEPT, 2024; INSPECTION CLOSED WITH ZERO OBSERVATIONS

DR. REDDY’S LABORATORIES: CO SAYS USFDA COMPLETED A ROUTINE GOOD MANUFACTURING PRACTICE (GMP) INSPECTION AT R&D CENTRE (INTEGRATED PRODUCT DEVELOPMENT ORGANISATION OR IPDO) IN BACHUPALLY, HYDERABAD

TORRENT PHARMA: CO SAYS END OF INSPECTION, AGENCY ISSUED FORM FDA 483 WITH ONE OBSERVATION -- FORM FDA 483 WITH ONE OBSERVATION IS PROCEDURAL IN NATURE

TORRENT PHARMA: CO SAYS USFDA CONDUCTED ROUTINE GMP INSPECTION OF FORMULATION MANUFACTURING FACILITY

LUPIN: THE US COURT OF APPEALS FOR THE FEDERAL CIRCUIT HAS VACATED A US DISTRICT COURT JUDGEMENT THAT FAVORED GENERIC COMPANIES IN THE PATENT LITIGATION AROUND GMYRBETRIQ AND REMANDED THE MATTER BACK TO THE DISTRICT COURT. - ETNOW

ZYDUS LIFE: THE US COURT OF APPEALS FOR THE FEDERAL CIRCUIT HAS VACATED A US DISTRICT COURT JUDGEMENT THAT FAVORED GENERIC COMPANIES IN THE PATENT LITIGATION AROUND GMYRBETRIQ AND REMANDED THE MATTER BACK TO THE DISTRICT COURT. - ETNOW

ASTRAZENECA PHARMA: CO TO LAUNCH PALIVIZUMAB (SYNAGIS) IN OCT IN INDIA FOR PREVENTION OF RSV-RELATED SERIOUS LOWER RESPIRATORY TRACT DISEASE IN HIGH-RISK CHILDREN

SHALBY: CO GROUP HAS RECEIVED LICENCE FOR PERFORMING BONE BANK

SUVEN PHARMA: CO NAMES MR. VIVEK SHARMA AS EXECUTIVECHAIRMAN -- VIVEK BRINGS TREMENDOUS CDMO AND LEADERSHIP EXPERTISE TO SUVEN, ACQUIRED ACROSS HIS ROLES AS CEO OF PIRAMAL PHARMA SOLUTIONS (2014-19)

DR. LAL PATHLABS: COS KENYA UNIT HAS BEEN DISSOLVE

DR REDDYS LABORATORIES LTD: RS. 205.53 CRORES NSE BLOCK TRADE; FOR ~ 316201 SHARES, AT RS. 6500.00

SHILPA MEDICARE: CO APPOINTED DR. SRIDEVI KHAMBHAMPATY AS CEO OF SHILPA BIOLOGICALS PVT. LTD, A WHOLLY OWNED SUBSIDIARY OF CO -- PREVIOUSLY WORK AT DR REDDYS, SYNGENE INTERNATIONAL

WOCKHARDT: COS INVESTIGATIONAL DRUG, ZAYNICH CURES COMPLEX CASE OF MENINGITIS CAUSED BY PAN-DRUG RESISTANT SUPER-BUG UNDER COMPASSIONATE USE

P&G: INITIAL FEEDBACK FROM NEW PRODUCT LAUNCHES HAVE BEEN POSITIVE -- FMCG VOLUME GROWTH IS EXPECTED TO BE IN MID-SINGLE DIGIT FOR FY25 -MANEGEMENT MEET

AUROBINDO PHARMA: PURCHASE CONSIDERATION AT 225M RUPEES

AUROBINDO PHARMA: CO ENTERED INTO A BINDING AGREEMENT WITH GLS PHARMA -- SHARES ACQUIRED AT PRICE OF 381.12 RUPEES PER SHARE

ASTER DM HEALTHCARE: THE MERGED ENTITY WILL RANK AMONG THE TOP THREE HOSPITAL CHAINS IN INDIA, IN TERMS OF NUMBER OF BEDS, ALONG WITH APOLLO HOSPITALS AND MANIPAL HOSPITALS- MC

ASTER DM HEALTHCARE: BLACKSTONE’S CARE HOSPITALS IN ADVANCED TALKS FOR MERGER WITH CO - MC

LUPIN: CO ENTERS INTO A NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDA TOCOMMERCIALIZE VONOPRAZAN, A NOVEL GASTROINTESTINAL DRUG IN INDIA

SUVEN LIFE SCIENCES: CO ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE-2A PROOF-OF-CONCEPT SIGNAL DETECTION OPEN LABEL STUDY OF ROPANICANT (SUVN-911) FOR THE TREATMENT OF MODERATE TO SEVERE MAJOR DEPRESSIVE DISORDER (MDD)

AUROBINDO: CO UNIT EUGIA STERILES PRIVATE, RECEIVES EIR FROM US FDA

MANKIND PHARMA: BOARD MEETING ON SEPT 20 TO CONSIDER AND APPROVE RAISING OF FUNDS

BIOCON: COS BIGGEST COMPETITOR COHERUS BIOSCIENCES FACING SUPPLY DISRUPTION IN KEY PRODUCT PEGFILGRASTIM

ZYDUS LIFESCIENCES : CO APPROVED BUSINESS TRANSFER AGREEMENT TO PURCHASE API BUSINESS OF SBL, DEAL OF 84 CR RUPEES

PIRAMAL PHARMA: CO HAS RECEIVED SBTI APPROVAL FOR ITS COMMITMENT TO REDUCE SCOPE 1 AND 2 GHG EMISSIONS BY 42% AND SCOPE 3 BY 25% BY FY 2030

STRIDES PHARMA SCIENCE: CO RECEIVES USFDA APPROVAL FOR FLUOXETINE TABS 60 MG -- US SALES OF USD130M

JUBILANT PHARMOVA LTD: Rs. 36.79 Crores NSE Block Trade; for ~ 301179 Shares, at Rs. 1221.50

AUROBINDO PHARMA: AURO STANDS TO GAIN THE MOST WITH 85% PRODUCT OVERLAP OPPORTUNITY SIZEGRANULES FORMULATION SALES TO US AT ~20M/MONTH, ~$250M ANNUALISED

AUROBINDO PHARMA: INVESTEC SAYS ADVERSE IMPACT FROM GRANULES GAGILLAPUR WILL CAUSE MAJOR DISRUPTION & CREATE MORE SUPPLY CHALLENGES IN THE US

DR. REDDYS LAB: CITIUS PHARMACEUTICALS - DR. REDDYS AGREED TO PARTIAL DEFERRAL WITHOUT PENALTY OF MILESTONE PAYMENT BY CITIUS ONCOLOGY INC -- CITIUS PHARMACEUTICALS INC - CO IS GUARANTOR OF OBLIGATIONS OF CITIUS ONCOLOGY, INC UNDER ASSET PURCHASE AGREEMENT - RTRS

LAURUS LABS: CO SAYS USFDA AUDIT COMPLETED TODAY FOR OUR API MANUFACTURING FACILITY AT HYDERABAD (DS-1, IKP KNOWLEDGE PARK, GENOME VALLEY, SHAMEERPET, TELANGANA) WITHOUT ANY 483 OBSERVATION

ARTEMIS MEDICARE SERVICES: CO HAS INFORMED ABOUT THE CAPACITY ADDITION (TOWER-III) IN THE CO’S FLAGSHIP HOSPITAL LOCATED AT GURUGRAM -- CO SAYS CONSTRUCTION OF SAID TOWER III WITH THE CAPACITY TO ACCOMMODATE 180 BEDS HAS BEEN COMPLETED AND IT WILL BE OPERATIONAL IN A GRADED MANNER

ZYDUS LIFESCIENCES: ZYDUS ANNOUNCES EXCLUSIVE LICENSING AND SUPPLY AGREEMENT FOR TWO GADOLINIUM BASED MAGNETIC RESONANCE IMAGING (MRI) INJECTABLE, CONTRAST AGENTS IN THE US -- TOTAL ADDRESSABLE MARKET OPPORTUNITY FOR GADOBUTROL INJECTION IS ESTIMATED AT US$ 120M, AND FOR GADOTERATE MEGLUMINE INJECTION AT US$ 117M IN THE US MARKET (AS PER IQVIA MAT JUL - 2024)

RPG LIFE SCIENCES: CO SAYS EXECUTION OF BINDING AGREEMENT WITH KRSNA DYNASTY; AGREEMENT WORTH 1.45B RUPEES -- AGREEMENT FOR ASSIGNMENT OF SURPLUS VACANT LEASEHOLD LAND

MAX HEALTHCARE: CO STRATEGIC COLLABORATION WITH LAKSHDEEP GROUP FOR REVIVAL AND TURNAROUND OF JAYPEE HEALTHCARE LTD

ALKEM LABS: CO MAY BE A BIDDER FOR JB CHEMICALS - ET

CONCORD BIOTECH: CO TO MEET ANALYSTS/INVESTOR ON 19 SEPTEMBER -- NAME OF THE INVESTORS NOT MENTIONED

GRANULES INDIA: CO SAYS ACTIVELY ADDRESSING THE OBSERVATIONS AND ARE FULLY COMMITTED TO RESOLVING THE ISSUES RAISED. -- AND ARE FULLY COMMITTED IN RESOLVING THE ISSUES

LUPIN: CO SAYS DEAL FOR 105.5M RUPEES -- CO SAYS UPTO 42.61% STAKE IN SUNSURE SOLARPARK TO BE ACQUIRED

LUPIN: CO SIGNED SHARE SUBSCRIPTION & SHAREHOLDERS AGREEMENT WITH SUNSURE SOLARPARK SEVENTEEN -- CO TO MAKE EQUITY INVESTMENT IN SUNSURE SOLARPARK

AUROBINDO: CO GETS APPROVAL FROM USFDA FOR EUGIA STERILES PRIVATE LIMITED, A 100% STEPDOWN SUBSIDIARY.

STRIDES: CO ANNOUNCES APPROVAL FROM EQUITY SHAREHOLDERS AND SECURED CREDITORS FOR CREATION OF ONESOURCE – INDIA’S FIRST SPECIALTY PHARMA CDMO

DR REDDYS LAB: CO ISSUES CLARIFICATION ON CERTAIN ALLEGATIONS PERTAINING TO OUR ENGAGEMENT WITH AGORA ADVISORY, CO ROUTINELY ENGAGE EXTERNAL COACHES TO ENABLE SIGNIFICANT ROLE TRANSITIONS OF LEADERS.

DR REDDYS LAB: CO SAYS ANY SUGGESTION CO WAS TREATED DIFFERENTLY BY SEBI WOULD BE "BASELESS AND MALAFIDE -- CO SAYS CONTINUES TO OPERATE IN COMPLIANCE WITH ALL APPLICABLE LAWS

DR REDDYS LAB: CO SAYS FOR LIMITED PERIOD FROM OCTOBER 2020 TO APRIL 2021, WE ENGAGED SERVICES OF DHAVAL BUCH -- CO SAYS ASSIGNMENT STARTED AND ENDED WELL BEFORE MADHABI BUCHS TERM AS SEBI CHAIRPERSON

DR REDDYS LAB: CO ISSUES CLARIFICATION ON CERTAIN ALLEGATIONS PERTAINING TO OUR ENGAGEMENT WITH AGORA ADVISORY -- CO SAYS ROUTINELY ENGAGE EXTERNAL COACHES TO ENABLE SIGNIFICANT ROLE TRANSITIONS OF LEADERS

JUBILANT PHARMOVA: USFDA DETERMINES INSPECTION CLASSIFICATION OF ‘VOLUNTARY ACTION INDICATED’ FOR THE CONTRACT MANUFACTURING FACILITY AT SPOKANE, WASHINGTON (USA)

ZYDUS LIFESCIENCES: CO ANNOUNCES COMPLETION OF PHASE II(A) CLINICAL TRIAL OF USNOFLAST, A NOVEL ORAL NLRP3 INFLAMMASOME INHIBITOR IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS)

UNICHEM LABORATORIES: CO SAYS USFDA HAS NOW CLASSIFIED INSPECTION AS VOLUNTARY ACTION INDICATED

MANKIND PHARMA LTD: RS. 196.28 CRORES NSE BLOCK TRADE; FOR ~ 800552 SHARES, AT RS. 2451.80

AARTI DRUGS: CO TO BUYBACK 6.65 LK SHRS (0.72% EQ) OF THE CO WORTH ₹59.85 CR AT ₹900/SH, BUYBACK OPENS ON SEPT 11 & CLOSES ON SEPT 18

BIOCON: GST COUNCIL - GST RATE ON CANCER DRUGS REDUCED FROM 12% TO 5%; AIMED AT REDUCING THE OVERALL COST OF CANCER TREATMENT SAYS INDIA FIN MIN

CIPLA: GST COUNCIL - GST RATE ON CANCER DRUGS REDUCED FROM 12% TO 5%; AIMED AT REDUCING THE OVERALL COST OF CANCER TREATMENT SAYS INDIA FIN MIN

ZYDUS LIFESCIENCES: GST COUNCIL - GST RATE ON CANCER DRUGS REDUCED FROM 12% TO 5%; AIMED AT REDUCING THE OVERALL COST OF CANCER TREATMENT SAYS INDIA FIN MIN

CIPLA: GST COUNCIL - GST RATE ON CANCER DRUGS REDUCED FROM 12% TO 5%; AIMED AT REDUCING THE OVERALL COST OF CANCER TREATMENT SAYS INDIA FIN MIN

MANKIND PHARMA LTD: RS. 62.39 CRORES NSE BLOCK TRADE; FOR ~ 254692 SHARES, AT RS. 2449.65

WOCKHARDT: CO CLARIFIES ON ALLEGATIONS PERTAINING TO PAYMENT OF RENT BY CAROL INFO SERVICES -- CO SAYS THESE ALLEGATIONS ARE COMPLETELY BASELESS AND MISLEADING

KRISHNA INSTITUTE: CO UNIT ENTERS INTO DEFINITIVE AGREEMENTS WITH SREECHAND SPECIALTY HOSPITALS -- AGREEMENTS TOWARDS LEASE OF LAND, BUILDING WITH OPS, MANAGEMENT OF HOSPITAL

MAX HEALTHCARE INSTITUTE LTD: RS. 54.26 CRORES NSE BLOCK TRADE; FOR ~ 606319 SHARES, AT RS. 894.90

SUN PHARMA: CO & MOEBIUS PLANNING FOR CONFIRMATORY PHASE 3 CLINICAL TRIALS FOR MM-II (LARGE LIPOSOMES OF DPPC AND DMPC) IS UNDERWAY

SUN PHARMA: CO & MOEBIUS ANNOUNCED THAT USFDA HAS GRANTED FAST TRACK DESIGNATION (FTD) TO MM-II FOR THE TREATMENT OF OSTEOARTHRITIS KNEE PAIN.

PFIZER LTD: RS. 69.39 CRORES NSE BLOCK TRADE; FOR ~ 112106 SHARES, AT RS. 6190.05

STRIDES PHARMA: CO RECEIVE USFDA APPROVAL FOR THEOPHYLLINE EXTENDED-RELEASE TABLETS, 300 MG AND 450 MG

DR. REDDY’S LABS: CO RECEIVES USFDA EIR FOR SRIKAKULAM FACILITY, INSPECTION CLASSIFIED AS VOLUNTARY ACTION INDICATED (VAI)

PFIZER LTD: RS. 58.81 CRORES NSE BLOCK TRADE; FOR ~ 95784 SHARES, AT RS. 6140.00

ALEMBIC PHARMA: CO ANNOUNCES USFDA FINAL APPROVAL FOR ALBENDAZOLE TABLETS USP, 200 MG

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA HAS REACHED A SETTLEMENT WITH THE U.S. DEPARTMENT OF JUSTICE, AGREEING TO PAY $25 MILLION OVER FIVE YEARS WITH INTEREST, FOLLOWING THE AUGUST 2023 DEFERRED PROSECUTION AGREEMENT, WITHOUT ADMITTING ADDITIONAL LIABILITY.

APOLLO HOSPITAL: APOLLO HEALTHCO LTD, AN UNLISTED MATERIAL WHOLLY OWNED SUBSIDIARY OF THE CO HAS INCORPORATED ITS WHOLLY OWNED SUBSIDIARY BY THE NAME APOLLO 24/7 INSURANCE SERVICES LTD

LUPIN: CO LAUNCHES MIRABEGRON EXTENDED-RELEASE TABLETS IN THE UNITED STATES -- US SALES OF USD 1.6B

SHILPA MEDICARE: CO ANNOUNCES SUBMISSION OF NDA TO U.S. FDA BY UNICYCIVE - ITS FIRST REGULATORY SUBMISSIONS FROM CDMO PARTNERED PROJECTS

APOLLO HOSPITALS ENTERPRISE: CO SUBSCRIBED TO 343,629 EQUITY SHARES OF ITS SUBSIDIARY APOLLO HEALTHCO LTD FOR RS 399.99 CRORE TO SUPPORT AHLS CAPITAL EXPANSION AND SETTLE PAYABLES.

NATCO PHARMA: NATCO PHARMA (CANADA) INC. ANNOUNCES USD 8 MLN INVESTMENT IN EGENESIS, INC.

FORTIS HEALTHCARE: CO TO SEEK SHAREHOLDERS NOD TO RAISE NCDS WORTH UP TO 15.50B RUPEES

MANKIND PHARMA: CO HAS EXECUTED THE BUSINESS TRANSFER AGREEMENT TO TRANSFER OVER THE COUNTER (OTC) BUSINESS UNDERTAKING OF THE CO AS A GOING CONCERN ON A SLUMP SALE BASIS TO UNIT MANKIND CONSUMER PRODUCTS PVT LTD (MCPPL)

GLAXOSMITHKLINE PHARMA: CO SAYS HAS RECEIVED INCOME TAX ORDER FROM INCOME TAX DEPT UNDER SECTION 143(3) FOR ASSESSMENT YEAR 2022-23, ISSUING INCOME TAX REFUND OF RS 222.23 CR (INCLUDING INTEREST)

ZYDUS LIFESCIENCES: CO ISSUES CLARIFICATION REGARDING RECEIPT OF WARNING LETTER FROM USFDA SAYS AUG 30 USFDA WARNING LETTER DOESNT IMPACT EXISTING PRODUCTS MADE IN JAROD UNIT

ORCHID PHARMA: CO SAYS GOT NO-OBJECTION LETTERS FROM BSE, NSE FOR MERGER OF DHANUKA LABORATORIES WITH CO

NSE INDEX PROVISIONALLY ENDS DOWN 0.04% OR -9.80 POINTS AT 25,268.90

KRISHNA INSTITUTE OF MEDICAL: CO. ANNOUNCES RECORD DATE OF SEPTEMBER 13, 2024 FOR SHARE SPLIT

MANKIND PHARMA LTD: RS. 73.55 CRORES NSE BLOCK TRADE; FOR ~ 301154 SHARES, AT RS. 2442.25

AUROBINDO PHARMA: CO TO STEP UP FOCUS ON BIOSIMILARS, LINES UP A SLEW OF PRODUCTS - BUSINESSLINE

BIOCON: CO SAYS THIS IS BASED ON A PRE-APPROVAL INSPECTION CONDUCTED BY THE AGENCY BETWEEN THE 10TH AND 14TH OF JUNE, 2024, AND NOW ALLOWS CO TO COMMENCE COMMERCIAL SUPPLIES FROM THIS FACILITY TO THE U.S. MARKET

BIOCON: CO HAS RECEIVED AN ESTABLISHMENT INSPECTION REPORT (EIR) FROM USFDA, FOR GREENFIELD API FACILITY (SITE 6), VISAKHAPATNAM, ANDHRA PRADESH

KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO ACQUIRED 100 % EQUITY STAKE OF CHALASANI HOSPITALS -- DEAL FOR 280M RUPEES

FORTIS HEALTHCARE: CO SAYS ACQUISITION BY CO OF ENTIRE STAKE HELD BY PE INVESTORS IN AGILUS DIAGNOSTICS -- CO SAYS FOR ACQUISITION OF STAKE IN ADL RAISING FUNDS THROUGH ISSUANCE OF DEBENTURES

GLAND PHARMA LTD: RS. 176.91 CRORES NSE BLOCK TRADE; FOR ~ 961442 SHARES, AT RS. 1840.00

ZYDUS LIFESCIENCES: CO WILL TAKE ALL NECESSARY STEPS TO WORK WITH USFDA TOWARDS EARLIEST REMEDIATION OF THE ABOVE FACILITY

ZYDUS LIFESCIENCES: CO RECEIVED A WARNING LETTER ISSUED BY THE USFDA

ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM USFDA FOR SCOPOLAMINE TRANSDERMAL SYSTEM -- US SALES OF USD 70M

CIPLA: CO IN AGM SAYS CO HAVE INITIATED PROCESS OF TRANSFER OF PRODUCTS TO OTHER FACILITIES

CIPLA: CO IN AGM SAYS DOING REMEDIATION BOTH IN GOA AND INDORE FACILITIES

ASTER DM HEALTHCARE LTD: Rs. 30.58 Crores NSE Block Trade; for ~ 751431 Shares, at Rs. 406.95

VIMTA LABS: CO SIGNS AGREEMENT TO TRANSFER DIAGNOSTICS BUSINESS TO THYROCARE TECHNOLOGIES FOR RUPEES 70M

PIRAMAL PHARMA: CO APPROVED SUBSCRIPTION OF SHARES WORTH EUR 139.3M OF PIRAMAL DUTCH HOLDINGS N.V.

TORRENT PHARMA: COS INDRAD FACILITY RECEIVES USFDA EIR WITH VOLUNTARY ACTION INDICATED CLASSIFICATION, SUCCESSFULLY CLOSING THE INSPECTION

LUPIN: CO LAUNCHES DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION IN THE UNITED STATES -- DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION (RLD DOXIL® (LIPOSOMAL)) HAD AN ESTIMATED ANNUAL SALES OF USD40.9M IN THE U.S. (IQVIA MAT JUNE 2024)

NATCO PHARMA: CO GETS ANDA APPROVAL FROM USFDA FOR TABRECTA® HAS RECORDED SALES OF USD 126 MILLION

SYNGENE INTERNATIONAL LTD: RS. 59.61 CRORES NSE BLOCK TRADE; FOR ~ 704531 SHARES, AT RS. 846.15

HCG: CO TO MEET GROUP OF INVESTER ON 4 SEP

GLAND PHARMA LTD: RS. 65.12 CRORES NSE BLOCK TRADE; FOR ~ 352760 SHARES, AT RS. 1846.00

BIOCON: CO UNIT SECURES MARKET ENTRY FOR BMAB 1200, A PROPOSED BIOSIMILAR TO STELARA, IN EUROPE, UK, CANADA, AND JAPAN

SHILPA MEDICARE: CO COMPLETES PHASE 1 TRIAL FOR RECOMBINANT HUMAN ALBUMIN (RHA) 20% - RTRS

DIVIS LABORATORIES LTD: RS. 88.38 CRORES NSE BLOCK TRADE; FOR ~ 180681 SHARES, AT RS. 4891.45

ZYDUS LIFE: CO RECEIVES FINAL APPROVAL FROM USFDA FOR AMANTADINE EXTENDED-RELEASE CAPSULES 68.5 MG AND TENTATIVE APPROVAL FOR 137 MG

SUVEN LIFE SCIENCES: CO ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG (IND) AND GRANT OF “STUDY MAY PROCEED LETTER” TO INITIATE PHASE-1 CLINICAL TRIAL OF SUVN-I6107, A TRUE MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR (M1-PAM)

SHILPA MEDICARE: CO MD SAYS THIS SECOND NDA APPROVAL IN THE US MARKET FROM OUR NOVEL INJECTABLE PORTFOLIO OF THE CO

SHILPA MEDICARE: CO GETS USFDA APPROVAL FOR BORTEZOMIB INJECTION NDA 212782

PFIZER LTD: RS. 64.31 CRORES NSE BLOCK TRADE; FOR ~ 109677 SHARES, AT RS. 5864.00

GLOBAL HEALTH: CO CLARIFIES ON MEDIA REPORT - ACQUISITION OF PARAMOUNT TPA, NOT PLANNING TO ACQUIRE STAKE IN PARAMOUNT TPA

ZYDUS LIFESCIENCES: CO SAYS THIS COULD LEAD TO A POTENTIAL COMPETITION AND IMPACT THE SALES AND PROFITS -- CO SAYS THE IMPACT OF THE SAME IS ALREADY FACTORED BY THE CO IN ITS SALES AND OPERATING PROFIT (EBITDA) EXPECTATIONS FOR FY2025

ZYDUS LIFESCIENCES: CO SAYS FURTHER, WE HAVE NOTED THAT AN APPROVAL FOR THE GENERIC PRODUCT IN THE NAME OF GASACOL HD (MESALAMINE 800 MG) OF THE CO, MARKETED IN THE UNITED STATES OF AMERICA, HAS BEEN GIVEN BY THE USFDA TO ANOTHER CO

ZYDUS LIFESCIENCES: CO ISSUES CLARIFICATION SAYS CO HAS GIVEN STATUTORY INTIMATION AND PRESS RELEASE REGARDING ACQUISITION OF 50% STAKE OF STERLING BIOTECH ON AUG 23, 2024 -- CO SAYS WE STRONGLY BELIEVE THAT TODAY’S MATERIAL PRICE MOVEMENT IN THE SHARES OF THE CO IS NOT ATTRIBUTABLE TO THIS EVENT

AMI ORGANICS: CO TO MEET IIFL CARAVAN ON 29 AUGUST

KRSNAA DIAGNOSTIC: CO TO MEET RTL INVESTMENTS ON AUG.27

AARTI DRUGS: CO BOARD OF DIRECTORS HAS SET SEPTEMBER 5 AS THE RECORD DATE FOR THE PLANNED BUYBACK

AARTI DRUGS: CO APPROVED BUYBACK OF SHARES AT 900 RUPEES PER SHARE VIA TENDER OFFER ROUTE

ASTER DM HEALTHCARE: CO SAYS BLACKSTONE MAY OWN 40% HOLDING, CO FOUNDERS MOOPEN FAMILY 20% , TGP 15% - ET NOW

ASTER DM HEALTHCARE: CO SAYS BLACKSTONE TO BE BIGGEST SHAREHOLDER IN MERGED ENTITY -ET NOW

SHILPA MEDICARE: CO PLANS TO SUBMIT THESE PHASE 3 CLINICAL TRIAL FINDINGS AT EARLIEST TO CDSCO

SHILPA MEDICARE: CO SAYS THERE WAS A SUCCESSFUL REDUCTION IN FAT ACCUMULATION IN LIVER

SHILPA MEDICARE: CO ANNOUNCES SUCCESSFUL OUTCOME OF PHASE 3 STUDIES OF SMLNUD07 – NORUDCA

DR. REDDY’S LABORATORIES: CO SAYS THE INSPECTION WAS CONDUCTED FROM AUG19, 2024 TO AUG 23, 2024 -- CO SAYS WE HAVE BEEN ISSUED A FORM 483 WITH THREE OBSERVATIONS, WHICH WE WILL ADDRESS WITHIN THE STIPULATED TIMELINE

DR. REDDY’S LABORATORIES: CO SAYS USFDA TODAY COMPLETED A PRODUCT-SPECIFIC PRE-APPROVAL INSPECTION (PAI) AT OUR FORMULATIONS MANUFACTURING FACILITY (FTO SEZ PU1) IN SRIKAKULAM, ANDHRA PRADESH

FDC: US-FDA INSPECTION AT FACILITY LOCATED AT BADDI -- AUDIT SUCCESSFULLY COMPLETED BY US FDA WITH NO OBSERVATIONS

SUN PHARMA: CO INTRODUCES STARIZO IN INDIA FOR ACUTE BACTERIAL SKIN, SKIN STRUCTURE INFECTIONS

SUN PHARMACEUTICAL INDUSTRIES LTD: RS. 284.42 CRORES NSE BLOCK TRADE; FOR ~ 1612832 SHARES, AT RS. 1763.50

HEALTHCARE GLOBAL: CO CLARIFIES ON NEWS ITEM "C-CARE AND HEALTHCARE GLOBAL ENTERPRISES INK PACT TO DELIVER CANCER CARE SERVICE" -- CO SAYS THIS ARRANGEMENT BETWEEN THE CO AND C-CARE HOSPITALS, AS COVERED IN THE NEWS ITEM, DOES NOT TANTAMOUNT TO A MATERIAL CONTRACT/INFORMATION

ALKEM LABS: RS 487.23CR NSE BLOCK TRADE; FOR ~850000 SHARES, AT RS 5732.15 (PRE-OPEN)

ERIS LIFESCIENCES LTD: RS. 1187.41 CRORES NSE BLOCK TRADE; FOR ~ 9886882 SHARES, AT RS. 1201.00

AARTI DRUGS: CO TO CONSIDER EQUITY SHARE BUYBACK ON AUGUST 26, 2024

ALKEM LABORATORIES: PROMOTER LIKELY TO SELL 0.7% STAKE (8.5 LAKH SHARES) OF ALKEM LABORATORIES VIA BLOCK DEALS -- FLOOR PRICE AT ₹5,616, AT A 3% DISCOUNT TO CMP - CNBCTV18, CITING SOURCES

SUN PHARMA: PHARMAZZ INC. AND SUN PHARMA ENTERED INTO AN AGREEMENT UNDER WHICH SUN PHARMA WILL INVEST UP TO $15M IN PHARMAZZ, INC.

PROCTER & GAMBLE HEALTH: CO HAS RECOMMENDED A FINAL DIVIDEND OF 60 RUPEES PER EQUITY SHARE

PROCTER & GAMBLE HEALTH: CO HAS AN EXCEPTIONAL ITEM OF LOSS 201.9M RUPEES -- Q1 PBT 430.2M RUPEES VS 441.3M (YOY)

PROCTER & GAMBLE HEALTH: Q1 EBITDA 482.5M RUPEES VS 453.4M (YOY) -- Q1 EBITDA MARGIN 17% VS 15.05% (YOY)

PROCTER & GAMBLE HEALTH: Q1 SL NET PROFIT 167.8M RUPEES VS 298.2M (YOY); 465.6M (QOQ) -- Q1 REVENUE 2.84B RUPEES VS 3.01B (YOY); 2.52B (QOQ)

INDOCO REMEDIES: CO RECEIVES FINAL ANDA APPROVAL FROM THE USFDA FOR LOFEXIDINE TABLETS 0.18 MG WITH COMPETITIVE GENERIC THERAPY DESIGNATION -- THIS TABLETS HAS US SALES OF USD 16M

MARKSANS PHARMA: CO UNIT RELONCHEM LIMITED RECEIVES MARKETING AUTHORIZATION FOR ITS PRODUCTS

APOLLO HOSPITALS ENTERPRISE: CCI APPROVES THE PROPOSED COMBINATION INVOLVING ACQUISITION BY ADVENT (THROUGH RASMELI) IN UNIT APOLLO HEALTHCO, ACQUISITION BY APOLLO HEALTHCO IN KEIMED AND MERGER OF KEIMED INTO APOLLO HEALTHCO

MARKSANS PHARMA: CO HAS RECEIVED AN ESTABLISHMENT INSPECTION REPORT (EIR) FROM THE USFDA FOR ITS GOA MANUFACTURING FACILITY, WITH THE INSPECTION BEING SUCCESSFULLY CLOSED AND CLASSIFIED AS "VOLUNTARY ACTION INDICATED" (VAI).

GRANULES INDIA: CO RECEIVES ANDA APPROVAL FOR GLYCOPYRROLATE ORAL SOLUTION

SIGACHI INDUSTRIES: CO INTRODUCES PURECOAT® AND ULTRAMOD™, INNOVATIVE PHARMACEUTICAL FILM COATINGS AND POLYMER BLENDS AIMED AT IMPROVING DRUG DELIVERY, PATIENT COMPLIANCE, AND PRODUCT EFFICACY.

KIMS: RS 184.11CR BSE BLOCK TRADE; FOR ~775758 SHARES, AT RS 2373.28 (PRE-OPEN)

POLY MEDICURE: POLY MEDICURE QIP LAUNCHED, ISSUE SIZE AT ₹1,000 CRORE & INDICATIVE PRICE AT ₹1,850-1,880/SH, AT A 11.6% DISCOUNT TO CMP -- EQUITY ON OFFER IS 5.54% SHARES - CNBCTV18, CITING SOURCES

SEQUENT SCIENTIFIC: CO SAYS MEPRO’S CHEWABLE FORMULATION IS THE FIRST GLOBAL APPROVAL OF ITS KIND BY THE WHO PQ -- ALBENDAZOLE IS A VITAL MEDICATION USED TO TREAT A RANGE OF PARASITIC INFECTIONS, INCLUDING TAPEWORM, ROUNDWORM, AND HOOKWORM INFESTATIONS, AFFECTING MILLIONS GLOBALLY, PARTICULARLY IN LOW AND MIDDLE INCOME COUNTRIES

SEQUENT SCIENTIFIC: CO RECEIVES WHO PREQUALIFICATION APPROVAL FOR ALBENDAZOLE API -- CO SAYS THIS IS IN PARTNERSHIP WITH MEPRO PHARMACEUTICALS, WHO HAVE SUCCESSFULLY DEVELOPED AND COMMERCIALISED THE ALBENDAZOLE CHEWABLE FORMULATION FROM ITS WHO PQ APPROVED PLANT, USING OUR API

STRIDES PHARMA SCIENCE: USFDA HAS DETERMINED THAT THE INSPECTION CLASSIFICATION OF THIS FACILITY IS “VOLUNTARY ACTION INDICATED

STRIDES PHARMA SCIENCE: CO GETS EIR FROM USFDA ON CONTINUED GMP STATUS FOR THE FACILITY IN ALATHUR, CHENNAI

GLENMARK PHARMA: GLENMARK THERAPEUTICS INC., USA LAUNCHES OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION USP, 0.1% (OTC)

CAPLIN POINT LABORATORIES: CO SAYS ANVISA- BRAZIL CONDUCTED AN INSPECTION OF UNIT CAPLIN STERILES’ INJECTABLE AND OPHTHALMIC MANUFACTURING FACILITY LOCATED AT GUMMIDIPOONDI -- CO SAYS THE INSPECTION WAS CONDUCTED BETWEEN AUG 12 AND 16, 2024 AND CONCLUDED WITH ZERO OBSERVATIONS

JUBILANT PHARMOVA: CO TO INVEST UP TO €14.4M OVER 7 YEARS, INCLUDING €4.4M FOR 80% STAKE IN THE NEW COMPANY -- PIERRE FABRE MAY HIRE SERVICES WORTH €7M FROM JUBILANT BIOSYS FOR FIRST 4 YEARS

JUBILANT PHARMOVA: CO UNIT JUBILANT BIOSYS TO ADD DRUG DISCOVERY & PRECLINICAL DEVELOPMENT CAPABILITIES IN BIOLOGICS AND ANTIBODY DRUG CONJUGATE -- CAPABILITIES TO BE ADDED VIA NEW COMPANY INCORPORATED IN FRANCE, WHICH WILL IN TURN ACQUIRE PIERRE FABRES R&D CENTRE IN THE COUNTRY

GLENMARK LIFE SCIENCES: CO GETS REVOCATION LETTER FROM GUJARAT POLLUTION CONTROL BOARD FOR ANKLESHWAR FACILITY

STRIDES PHARMA SCIENCE: CO SAYS UNIT ALTIMA INNOVATIONS, INC, US (ALTIMA), IS DISSOLVED EFFECTIVE AUGUST 13, 2024 -- CO SAYS ALTIMA HAS CEASED TO EXIST AS A CO AND A SUBSIDIARY OF STRIDES GROUP

TARSONS PRODUCTS: Q1 EBITDA 170M RUPEES VS 212M (YOY) -- Q1 EBITDA MARGIN 26.19% VS 33.87% (YOY)

TARSONS PRODUCTS: Q1 SL NET PROFIT 65M RUPEES VS 96M (YOY); 188M (QOQ) -- Q1 REVENUE 649M RUPEES VS 626M (YOY)

GLENMARK PHARMA: Q1 EBITDA 5.9B RUPEES VS 4.4B (YOY) -- Q1 EBITDA MARGIN 18.13% VS 14.40% (YOY)

GLENMARK PHARMA: Q1 CONS NET PROFIT 3.4B RUPEES VS 1.50B (YOY); LOSS 12B (QOQ) -- Q1 REVENUE 32.4B RUPEES VS 30.4B (YOY)

GUFIC BIOSCIENCES: Q1 EBITDA 358M RUPEES VS 355M (YOY) -- Q1 EBITDA MARGIN 17.64% VS 18.19% (YOY)

GUFIC BIOSCIENCES: Q1 REVENUE 2B RUPEES VS 1.95B (YOY)

GUFIC BIOSCIENCES: Q1 SL NET PROFIT 208M RUPEES VS 206M (YOY)

SUN PHARMA: CO SAYS INVESTMENT RESULTING IN MORE THAN 5% HOLDING IN PHARMAZZ INC

SUN PHARMA: CO TO INVEST UPTO $15 MN INVESTMENT IN PHARMAZZ INC

ORCHID PHARMA: COS TARGET FOR A SPECIFIC INITIATIVE IS INR100 CRORES IN THREE TO FOUR YEARS -- CO EXPECTS TO SEE SALES IN INDIA BY MARCH 2027, PENDING PRODUCT REGISTRATION. - CONCALL UPDATE

ORCHID PHARMA: CO IS MAINTAINING ITS GUIDANCE OF RS 100 CR FOR THE AMS DIVISION IN THREE TO FOUR YEARS -- COS LONG-TERM GUIDANCE FOR THE FULL YEAR REMAINS UNCHANGED AT 20% TO 25% GROWTH - CONCALL UPDATE

DISHMAN CARBOGEN AMCIS: Q1 EBITDA 300M RUPEES VS 1.2B (YOY) -- Q1 EBITDA MARGIN 5.73% VS 16.73% (YOY)

DISHMAN CARBOGEN AMCIS: Q1 CONS NET LOSS 776M RUPEES VS 170M (YOY) -- Q1 REVENUE 5.23B RUPEES VS 7.23B (YOY)

MARKSANS PHARMA: Q1 EBITDA 1.3B RUPEES VS 1.02B (YOY) -- Q1 EBITDA MARGIN 21.72% VS 20.4% (YOY)

MARKSANS PHARMA: Q1 CONS NET PROFIT 888M RUPEES VS 686M (YOY); 783M (QOQ) -- Q1 REVENUE 5.9B RUPEES VS 5B (YOY)

APOLLO HOSPITALS ENTERPRISE: Q1 EBITDA 6.75B RUPEES VS 5.1B (YOY); 6.78B EST -- Q1 EBITDA MARGIN 13.27% VS 11.52% (YOY); 13.3% EST

APOLLO HOSPITALS ENTERPRISE: Q1 CONS NET PROFIT 3.05B RUPEES VS 1.66B (YOY); 2.74B EST - 2.5B (QOQ) -- Q1 REVENUE 50.85B RUPEES VS 44B (YOY); 50.78B EST

YATHARTH HOSPITAL & TRAUMA CARE SERVICES: Q1 EBITDA 546M RUPEES VS 414M (YOY) -- Q1 EBITDA MARGIN 25.78% VS 26.8% (YOY)

YATHARTH HOSPITAL & TRAUMA CARE SERVICES: Q1 CONS NET PROFIT 304M RUPEES VS 190M (YOY); 383M (QOQ) -- Q1 REVENUE 2.1B RUPEES VS 1.55B (YOY)

SHALBY: CO ANNOUNCES STRATEGIC CLINICAL TRIAL AGREEMENT WITH MONOGRAM TECHNOLOGIES -- MONOGRAM TECHNOLOGIES IS AN AI-DRIVEN ROBOTICS COMPANY FOCUSED ON IMPROVING HUMAN HEALTH, WITH AN INITIAL FOCUS ON ORTHOPEDIC SURGERY

RAINBOW CHILDRENS MEDICARE: Q1 EBITDA 937.2M RUPEES VS 877M (YOY) -- Q1 EBITDA MARGIN 28.38% VS 30.54% (YOY)

RAINBOW CHILDRENS MEDICARE: Q1 CONS NET PROFIT 395.3M RUPEES VS 410M (YOY); 510M (QOQ) -- Q1 REVENUE 3.3B RUPEES VS 2.87B (YOY); 3.4B (YOY)

IPCA LABORATORIES: Q1 EBITDA 3.92B RUPEES VS 3.07B (YOY) -- Q1 EBITDA MARGIN 18.75% VS 19.38% (YOY)

IPCA LABORATORIES: Q1 REVENUE 21B RUPEES VS 15.9B (YOY)

IPCA LABORATORIES: Q1 CONS NET PROFIT 1.92B RUPEES VS 1.63B (YOY)

CIPLA LTD: RS. 81.32 CRORES NSE BLOCK TRADE; FOR ~ 510688 SHARES, AT RS. 1592.30

ALEMBIC PHARMACEUTICALS: CO ANNOUNCES USFDA DABIGATRAN ETEXILATE CAPSULES, 110 MG.

ERIS LIFESCIENCES LTD: RS. 79.89 CRORES NSE BLOCK TRADE; FOR ~ 665770 SHARES, AT RS. 1200.00

AMI ORGANICS: CO MD SAYS LOOKING AT OUR CURRENT ORDER BOOK, I AM CONFIDENT THAT WE WILL COMFORTABLY MEET OUR 25% GROWTH GUIDANCE FOR THE YEAR - INVESTOR PRESENTATION

CONCORD BIOTECH: CO HAS A ROBUST PIPELINE OF 8-10 NEW PRODUCTS TO BE COMMERCIALIZED OVER THE NEXT 3-4 YEARS -- CO SAYS MANY NEW PRODUCTS PLANNED FOR LAUNCH IN THE COMING YEARS ARE BEING TAKEN UP AT THE LIMBASI FACILITY, WHICH IS SCALING UP AS PLANNED - CONCALL UPDATE

CONCORD BIOTECH: CO EXPECTS THE INJECTABLE PLANT TO START CONTRIBUTING SIGNIFICANTLY OVER THE NEXT TWO TO THREE YEARS, WHICH WOULD SLIGHTLY IMPROVE THE FORMULATION MARGIN - CONCALL UPDATE

CONCORD BIOTECH: CO REITERATES ITS LONG-TERM CAGR GUIDANCE OF REVENUE GROWTH OF 25% OVER A PERIOD OF FIVE YEARS -- CO STANDS BY ITS LONG-TERM GUIDANCE OF 80-20, WHICH IS 20% FORMULATION AND 80% API - CONCALL UPDATE

AMI ORGANICS: CO IS EXPANDING ITS CAPACITY FOR VC, FVC UP TO 2,000 METRIC TONS, BASED ON A LONG-TERM CONTRACT FOR ELECTROLYTE ADDITIVES -- CO IS WORKING ON NEW APPLICATIONS AND OPPORTUNITIES WITH A CDMO IN THE SEMICONDUCTOR SEGMENT IN JAPAN AND KOREA - CONCALL UPDATE

AMI ORGANICS: CO SAYS 16-MEGAWATT SOLAR CAPEX CAPTIVE POWER PLANT PROJECT HAS BEEN INITIATED TO REDUCE CARBON EMISSIONS AND LOWER ENERGY COSTS, WITH COMPLETION EXPECTED BY THE END OF Q2 FY 25 - CONCALL UPDATE

AMI ORGANICS: CO ANTICIPATES SIMILAR STRONG SUBSTANTIAL GROWTH IN THE COMING QUARTER -- CO IS CONFIDENT THAT IT WILL COMFORTABLY MEET ITS 25% GROWTH GUIDANCE FOR THE YEAR BASED ON ITS CURRENT ORDER BOOK - CONCALL UPDATE

ORCHID PHARMA: Q1 EBITDA 325M RUPEES VS 221M (YOY) -- Q1 EBITDA MARGIN 13.29% VS 12.10% (YOY)

ORCHID PHARMA: Q1 CONS NET PROFIT 294M RUPEES VS 94M (YOY); 335M (QOQ) -- Q1 REVENUE 2.4B RUPEES VS 1.83B (YOY)

AMI ORGANICS: Q1 EBITDA 263M RUPEES VS 254M (YOY) -- Q1 EBITDA MARGIN 15.35% VS 17.82% (YOY)

AMI ORGANICS: Q1 SL NET PROFIT 137.2M RUPEES VS 169M (YOY); 321M (QOQ) -- Q1 REVENUE 1.71B RUPEES VS 1.42B (YOY); 2.2B (QOQ)

NATCO PHARMA: CO DECLARED INTERIM DIVIDEND OF RS 3 PER SHARE

NATCO PHARMA: Q1 REVENUE 13.6B RUPEES VS 11.4B (YOY)

NATCO PHARMA: Q1 EBITDA 8.05B RUPEES VS 5.28B (YOY) -- Q1 EBITDA MARGIN 59.06% VS 46.30% (YOY)

NATCO PHARMA: Q1 CONS NET PROFIT 6.7B RUPEES VS 4.2B (YOY)

MOREPEN LABORATORIES: Q1 EBITDA 516M RUPEES VS 261M (YOY) -- Q1 EBITDA MARGIN 11.34% VS 6.51% (YOY)

MOREPEN LABORATORIES: Q1 REVENUE 4.55B RUPEES VS 4B (YOY)

MOREPEN LABORATORIES: Q1 CONS PROFIT 362M RUPEES VS 146M (YOY)

BIOCON: CO EXPANDS CAPACITIES TO MEET GROWING DEMAND, PLANS FUTURE INVESTMENTS FOR POST - 2030 SEMAGLUTIDE MARKET - CONCALL UPDATE

BIOCON: CO IS PLANNING NEW GENERIC FORMULATION LAUNCHES ACROSS MULTIPLE MARKETS IN THE SECOND HALF OF THE FISCAL YEAR - CONCALL UPDATE

BIOCON: CO MENTIONED THE LAUNCH OF ITS LIRAGLUTIDE FORMULATIONS FOR DIABETES AND OBESITY IN THE UK AND OTHER MARKETS WHERE PREPARATIONS ARE UNDERWAY - CONCALL UPDATE

BIOCON: CO EXPECTS A HIGH SINGLE-DIGIT KIND OF GROWTH LEVELS FOR THE BUSINESS OVERALL YEAR - CONCALL UPDATE

BIOCON: CO EXPECTS THE QUARTER ONE TRENDS TO CONTINUE INTO QUARTER TWO BEFORE SEEING A TRANSITION TOWARD ACCELERATING GROWTH ACROSS THE BUSINESSES THROUGH THE SECOND HALF OF THE FISCAL YEAR AND INTO NEXT YEAR - CONCALL UPDATE

BIOCON: COS UNDERLYING GROUP FINANCIAL PERFORMANCE, AFTER ADJUSTING FOR THE ERIS TRANSACTION, HAS COME IN LINE WITH THEIR EXPECTATIONS AND PREVIOUS GUIDANCE - CONCALL UPDATE

ZYDUS LIFESCIENCES:SARO IS EXPECTED TO BE COMMERCIALIZED IN CALENDAR YEAR 2027 -- CO PLANS TO ESTABLISH A COMMERCIALLY READY FOOTPRINT IN THE US BY THE TIME SARO IS LAUNCHED - CONCALL UPDATE

ZYDUS LIFESCIENCES: CO EXPECTS A DOUBLE-DIGIT GROWTH IN THE US, FACTORING IN THE CURRENT BASE BUSINESS AND NEW PRODUCT LAUNCHES -- CO EXPECTS AROUND 25-PLUS LAUNCHES FOR THE FULL YEAR - CONCALL UPDATE

ZYDUS LIFESCIENCES: CO EXPECTS TO DELIVER HIGH TEENS GROWTH FOR THE CURRENT YEAR -- CO EXPECTS AN IMPROVEMENT IN MARGIN BY 100 BASIS POINTS TO 150 BASIS POINTS FROM FY24 MARGINS -- CO EXPECTS AROUND AN 8% KIND OF SPEND ON R&D AND HOPES TO MAINTAIN IT - CONCALL UPDATE

SUVEN PHARMA: Q1 EBITDA RUPEES 799.3M RUPEES VS 1.68B (YOY) -- Q1 EBITDA MARGIN 34.65% VS 48.27% (YOY)

SUVEN PHARMA: Q1 CONS NET PROFIT 607.7M RUPEES VS 1.21B (YOY); 533.6M (QOQ) -- Q1 REVENUE 2.31B RUPEES VS 3.48B (YOY); 2.53B (QOQ)

WOCKHARDT: Q1 EBITDA 910M RUPEES VS 160M (YOY) -- Q1 EBITDA MARGIN 12.31% VS 2.48% (YOY)

WOCKHARDT: Q1 CONS NET LOSS 160M RUPEES VS LOSS 1.3B (YOY) -- Q1 REVENUE 7.4B RUPEES VS 6.4B (YOY)

ALKEM LAB: COS US SALES FOR Q1FY25 STOOD AT RS 6,416 MILLION, WITNESSING A DECLINE OF 7.7% YOY AND A GROWTH OF 2.8% ON A QOQ BASIS

ALKEM LABORATORIES: Q1 EBITDA 6.1B RUPEES VS 3.89B (YOY) -- Q1 EBITDA MARGIN 20.08% VS 13.16% (YOY)

ALKEM LABORATORIES: Q1 REVENUE 31B RUPEES VS 29.67B (YOY)

ALKEM LABORATORIES: Q1 CONS NET PROFIT 5.45B RUPEES VS 2.9B (YOY)

ZYDUS LIFESCIENCES: Q1 REVENUE 62B RUPEES VS 51.39B (YOY); 56.5B EST

ZYDUS LIFESCIENCES: Q1 EBITDA 20.84B RUPEES VS 15.05B (YOY); EST 16.35B -- Q1 EBITDA MARGIN 33.57% VS 29.3% (YOY); EST 28.9%

ZYDUS LIFESCIENCES: Q1 CONS NET PROFIT 14B RUPEES VS 11B (YOY); 11.4B EST

CONCORD BIOTECH: Q1 EBITDA 813M RUPEES VS 722M (YOY) -- Q1 EBITDA MARGIN 37.66% VS 37.03% (YOY)

CONCORD BIOTECH: Q1 REVENUE 2.15B RUPEES VS 1.9B (YOY)

CONCORD BIOTECH: Q1 SL NET PROFIT 582M RUPEES VS 485M (YOY)

ASTER DM HEALTHCARE LTD: RS. 81.74 CRORES NSE BLOCK TRADE; FOR ~ 2040246 SHARES, AT RS. 400.65

ZYDUS LIFE: CO RECEIVES FINAL APPROVAL FROM USFDA FOR VALBENAZINE CAPSULES -- US SALES OF USD 2B

GRANULES INDIA: CO ANNOUNCES ANDA APPROVAL FOR TRAZODONE TABLETS -- US SALES OF APPROXIMATELY $128 MILLION

ALEMBIC PHARMA: CO EXPECTS TO MAINTAIN A CAGR IN THE ANIMAL HEALTH BUSINESS SIMILAR TO WHAT IT HAS ACHIEVED OVER THE LAST THREE YEARS -- CO TARGETS TO DELIVER A FEW BASIS POINTS HIGHER THAN THE IPM IN THE INDIA BUSINESS OVER A LONG-TERM CONSISTENT BASIS - CONCALL UPDATE

ALEMBIC PHARMA: CO EXPECTS EBITDA MARGINS TO IMPROVE OVER A TWO, THREE YEAR PERIOD, REACHING 18% TO 20% RANGES AS NEW FACILITIES GET BETTER UTILIZED AND R&D IS OPTIMIZED - CONCALL UPDATE

ALEMBIC PHARMA: CO EXPECTS TO GROW THE U.S. BUSINESS BY 10% TO 12%, OR 10% TO 15%, THIS YEAR -- CO EXPECTS TO CLOSE AT AROUND RS 550 CR FOR THIS YEAR ON THE R&D SIDE - CONCALL UPDATE

BIOCON: CO HAS OTHER INCOME OF 11B IN CURRENT QUARTER RESULTS

BIOCON: Q1 EBITDA 6.2B RUPEES VS 7.14B (YOY) -- Q1 EBITDA MARGIN 18.07% VS 20.87% (YOY)

BIOCON: Q1 CONS NET PROFIT 6.6B RUPEES VS 1.01B (YOY); 1.4B (QOQ) -- Q1 REVENUE 34.3B RUPEES VS 34B (YOY)

HEALTHCARE GLOBAL ENTERPRISES: Q1 EBITDA 988M RUPEES VS 743M (YOY) -- Q1 EBITDA MARGIN 18.84% VS 16.16% (YOY)

HEALTHCARE GLOBAL ENTERPRISES: Q1 CONS NET PROFIT 121M RUPEES VS 76M (YOY) -- Q1 REVENUE 5.2B RUPEES VS 4.60B (YOY)

GLOBAL HEALTH: Q1 CONS NET PROFIT 1.06B RUPEES VS 1.02B (YOY); 1.3B (QOQ) -- Q1 REVENUE 8.6B RUPEES VS 7.73B (YOY)

J.B.CHEMICALS & PHARMA: Q1 EBITDA 2.7B RUPEES VS 2.32B (YOY) -- Q1 EBITDA MARGIN 28.71% VS 25.9% (YOY)

J.B.CHEMICALS & PHARMA: Q1 CONS NET PROFIT 1.7B RUPEES VS 1.42B (YOY); 1.26B (QOQ) -- Q1 REVENUE 9.5B RUPEES VS 8.5B (YOY)

GLOBAL HEALTH: Q1 EBITDA 1.86B RUPEES VS 1.84B (YOY) -- Q1 EBITDA MARGIN 21.64% VS 23.66% (YOY)

GLOBAL HEALTH: Q1 REVENUE 8.61B RUPEES VS 7.8B (YOY); 8.09B (QOQ)

GLOBAL HEALTH: Q1 CONS NET PROFIT 1.06B RUPEES VS 1.02B (YOY); 1.27B (QOQ)

ARTEMIS MEDICARE: Q1 EBITDA 361.7M RUPEES VS 279M (YOY) -- Q1 EBITDA MARGIN 16.2% VS 13.31% (YOY)

ARTEMIS MEDICARE: Q1 REVENUE 2.23B RUPEES VS 2.09B (YOY); 2.25B (QOQ)

ARTEMIS MEDICARE: Q1 CONS NET PROFIT 166.7M RUPEES VS 98M (YOY); 141.8M (QOQ)

SHILPA MEDICARE: Q1 EBITDA 736M RUPEES 479M (YOY) -- Q1 EBITDA MARGIN 25.16% VS 18.42% (YOY)

SHILPA MEDICARE: Q1 REVENUE 2.9B RUPEES VS 2.6B (YOY)

SHILPA MEDICARE: Q1 CONS NET PROFIT 141M RUPEES VS 12M (YOY)

ASTRAZENECA PHARMA: Q1 REVENUE 3.9B RUPEES VS 2.95B (YOY)

ASTRAZENECA PHARMA: CO HAS AN EXCEPTIONAL ITEM OF 575M RUPEES -- LOSS AFTER TAX 118M RUPEES

ASTRAZENECA PHARMA: Q1 EBITDA 380M RUPEES VS 672M (YOY) -- Q1 EBITDA MARGIN 9.82% VS 22.76% (YOY)

ASTRAZENECA PHARMA: Q1 SL PROFIT BEFORE TAX 424M RUPEES VS 714M (YOY)

LUPIN: COS GENERIC HEALTH PTY INCORPORATED LUPIN NZ

ALEMBIC PHARMA: CO SAYS US BUSINESS GREW BY 18% DURING THE QUARTER

ALEMBIC PHARMA: Q1 EBITDA 2.37B RUPEES VS 1.98B (YOY) -- Q1 EBITDA MARGIN 15.16% VS 13.32% (YOY)

ALEMBIC PHARMA: Q1 REVENUE 15.62B RUPEES VS 14.86B (YOY)

ALEMBIC PHARMA: Q1 CONS NET PROFIT 1.35B RUPEES VS 1.2B (YOY)

UNICHEM LABORATORIES: Q1 EBITDA 435M RUPEES VS 280M (YOY) -- Q1 EBITDA MARGIN 9.74% VS 6.62% (YOY)

UNICHEM LABORATORIES: Q1 REVENUE 4.5B RUPEES VS 4.2B (YOY)

UNICHEM LABORATORIES: Q1 CONS NET PROFIT 92M RUPEES VS LOSS 7M (YOY)

KOPRAN: Q1 EBITDA 196M RUPEES VS 86M (YOY) -- Q1 EBITDA MARGIN 14.05% VS 7.39% (YOY)

KOPRAN: Q1 REVENUE 1.4B RUPEES VS 1.17B (YOY)

KOPRAN: Q1 CONS NET PROFIT 110M RUPEES VS 27.7M (YOY)

LINCOLN PHARMA: Q1 EBITDA 227M RUPEES VS 207M (YOY) -- Q1 EBITDA MARGIN 15.43% VS 15.27% (YOY)

LINCOLN PHARMA: Q1 REVENUE 1.47B RUPEES VS 1.35B (YOY)

LINCOLN PHARMA: Q1 SL NET PROFIT 237M RUPEES VS 190M (YOY)

CAPLIN POINT LAB: CO SAYS CAPLIN STERILES GETS USFDA APPROVAL FOR TIMOLOL MALEATE OPHTHALMIC SOLUTION

BLUE JET HEALTHCARE: CO HAS CLEAR VISIBILITY OF 3-4 PRODUCTS THAT ARE PARTLY COMMERCIALIZED OR IN VALIDATION, GUIDING FY 26 CAPEX -- ANOTHER RS 200 CR OF CAPEX IS COMMITTED TO BE SPENT BETWEEN 12-18 MONTHS - CONCALL UPDATE

BLUE JET HEALTHCARE: CO EXPECTS A SINGLE-DIGIT GROWTH IN OFFTAKE FROM NEXT JANUARY -- CO EXPECTS A HIGHER FORECAST FOR NEXT YEAR COMPARED TO THE CURRENT YEAR - CONCALL UPDATE

CAPLIN POINT LAB: CO PLANS TO MAKE 2-3 MEANINGFUL ACQUISITIONS IN THE FUTURE -- CO IS EXPECTING TO LAUNCH 20-30 PRODUCTS IN MEXICO WITHIN THE NEXT YEAR - CONCALL UPDATE

CAPLIN POINT LAB: CO SAYS GROSS MARGIN IS EXPECTED TO BE AROUND 65% IN THE FUTURE -- CO EXPECTS THE CONTRIBUTION MARGINS TO INCREASE FURTHER WITH THE ADDITION OF CAPLIN ONE LABS ONCOLOGY PRODUCTS - CONCALL UPDATE

CAPLIN POINT LAB: CO PLANS TO SOURCE AND OUTSOURCE PRODUCTS WITH ITS CASH RESOURCE, BUYING AND SELLING FROM WHOLESALERS IN THE USA, WHICH HAS AN EFFECTIVE SECOND LAYER OF DISTRIBUTION HIERARCHY - CONCALL UPDATE

AARTI DRUGS: CO RECEIVES CONDITIONAL RESTART DIRECTIONS FROM MPCB FOR T-150 UNIT AT TARAPUR, MAHARASHTRA

KRISHNA INSTITUTE OF MEDICAL SCIENCES: Q1 EBITDA 1.8B RUPEES VS 1.57B (YOY) -- Q1 EBITDA MARGIN 26.06% VS 25.92% (YOY)

KRISHNA INSTITUTE OF MEDICAL SCIENCES: Q1 CONS NET 866M PROFIT RUPEES VS 808M (YOY); 655M (QOQ) -- Q1 REVENUE 6.9B RUPEES VS 6.06B (YOY)

DR. LAL PATH LABS: CO DECLARED DIVIDEND OF 6 RUPEES PER SHARE

DR. LAL PATH LABS: Q1 EBITDA 1.7B RUPEES VS 1.5B (YOY) -- Q1 EBITDA MARGIN 28.24% VS 27.02% (YOY)

DR. LAL PATH LABS: Q1 REVENUE 6B RUPEES VS 5.4B (YOY)

DR. LAL PATH LABS: Q1 CONS NET PROFIT 1.1B RUPEES VS 826M (YOY)

FDC: Q1 REVENUE 6.4B RUPEES VS 5.4B (YOY)

FDC: Q1 EBITDA 1.46B RUPEES VS 1.22B (YOY) -- Q1 EBITDA MARGIN 22.97% VS 22.75% (YOY)

FDC: Q1 CONS NET PROFIT 1.19B RUPEES VS 1.1B (YOY)

ALEMBIC PHARMA: CO ANNOUNCES USFDA FINAL APPROVAL FOR ACITRETIN CAPSULES USP

CAPLIN POINT LAB: CO RECOMMENDED A FINAL DIVIDEND OF 2.5 RUPEES

CAPLIN POINT LAB: Q1 EBITDA 1.7B RUPEES VS 1.39B (YOY) -- Q1 EBITDA MARGIN 35.7% VS 34% (YOY) - AS PER CO STATEMENT

CAPLIN POINT LAB: Q1 EBITDA 1.51B RUPEES VS 1.27B (YOY) -- Q1 EBITDA MARGIN 33.08% VS 32.01% (YOY)

CAPLIN POINT LAB: Q1 REVENUE 4.6B RUPEES VS 3.95B (YOY)

CAPLIN POINT LAB: Q1 CONS NET PROFIT 1.24B RUPEES VS 1.03B (YOY)

SHILPA MEDICARE: CO IS PLEASED TO ANNOUNCE THE SUCCESSFUL COMPLETION OF ITS PHASE 1 CLINICAL TRIAL FOR RECOMBINANT HUMAN ALUBUMIN

GLAND PHARMA: CO SAYS REAFFIRMED OUTLOOK - WE EXPECT POSITIVE EBITDA FOR Q4 OF THIS FISCAL YEAR AND A POSITIVE EBITDA FOR THE NEXT FISCAL YEAR, DRIVEN BY INCREASED REVENUE EXCEEDING THE €200 MILLION THRESHOLD.- INVESTOR PRESENTATION

GLAND PHARMA: CO SAYS Q2FY25 IMPACT - LOWER ACTIVITY LEVELS ARE EXPECTED DUE TO THE EUROPEAN HOLIDAY SEASON AND PLANNED SUMMER MAINTENANCE SHUTDOWNS. THE FONTENAY PLANT WILL HAVE AN EXTENDED 3-WEEK SHUTDOWN FOR NEW AMPOULE LINE INSTALLATION- INVESTOR PRESENTATION

GLAND PHARMA: CO EXPECTS TO GENERATE APPROXIMATELY EUR 10M IN REVENUE IN 2025 FROM A NEW LINE -- CO GUIDED FOR MID-TEENS YEAR-ON-YEAR GROWTH - CONCALL UPDATE

SIMPLEX CASTINGS: CO BAGS ORDER WORTH RS. 25 CR FROM SAIL

FORTIS HEALTHCARE: CO SAYS DURING Q1FY25, THE NUMBER OF ROBOTIC SURGERIES CONDUCTED INCREASED BY 59% AND NEURO & SPINE SURGERIES BY 23% COMPARED TO CORRESPONDING PREVIOUS YEAR PERIOD - INVESTOR PRESENTATION

LUPIN: Q1 EBITDA 12.4B RUPEES VS 8.56B (YOY); EST 10.17B -- Q1 EBITDA MARGIN 22.16% VS 17.79% (YOY); EST 19.8%

LUPIN: Q1 CONS NET PROFIT 8B RUPEES VS 4.5B (YOY); EST 5.65B - 3.6B (QOQ) -- Q1 REVENUE 55B RUPEES VS 48.1B (YOY); EST 54.5B

FORTIS HEALTHCARE: Q1 EBITDA 3.4B RUPEES VS 2.7B (YOY) -- Q1 EBITDA MARGIN 18.43% VS 16.44% (YOY)

FORTIS HEALTHCARE: Q1 CONS NET PROFIT 1.65B RUPEES VS 1.1B (YOY); 1.78B (QOQ) -- Q1 REVENUE 18.6B RUPEES VS 16.6B (YOY)

KRSNAA DIAGNOSTICS: Q1 EBITDA 427M RUPEES VS 314M (YOY) -- Q1 EBITDA MARGIN 25.09% VS 22.49% (YOY)

KRSNAA DIAGNOSTICS: Q1 CONS NET PROFIT 179M RUPEES VS 146M (YOY); 187M (QOQ) -- Q1 REVENUE 1.7B RUPEES VS 1.39B (YOY)

SIGACHI INDUSTRIES: Q1 EBITDA 210.3M RUPEES VS 163.1M (YOY) -- Q1 EBITDA MARGIN 21.97% VS 19.26% (YOY)

SIGACHI INDUSTRIES: Q1 REVENUE 957.1M RUPEES VS 847M (YOY); 1.04B (QOQ)

SIGACHI INDUSTRIES: Q1 CONS NET PROFIT 131.6M RUPEES VS 108.8M (YOY); 150.4M (QOQ)

AUROBINDO PHARMA: CO RECEIVES USFDA APPROVAL FOR ESTRADIOL VAGINAL INSERTS USP, 10 MCG --APPROVED PRODUCT HAS AN ESTIMATED MARKET SIZE OF US$268M FOR THE TWELVE MONTHS ENDING JUNE 2024, ACCORDING TO IQVIA

GLAND PHARMA: CO EXPECTS POSITIVE EBITDA FOR NEXT FISCAL YEAR FOR CENEXI

GLAND PHARMA: Q1 EBITDA 2.6B RUPEES VS 2.98B (YOY) -- Q1 EBITDA MARGIN 18.86% VS 25.00% (YOY)

GLAND PHARMA: Q1 CONS NET PROFIT 1.44B RUPEES VS 1.94B (YOY); 1.9B (QOQ) -- Q1 REVENUE 14B RUPEES VS 12.09B (YOY)

IPCA: CO LAUNCHES "DIULCUS IN THE INDIAN MARKET FOR TREATMENT OF DIABETIC FOOT ULCER (DFU)

BLUE JET HEALTHCARE: Q1 EBITDA 442M RUPEES VS 590M (YOY) -- Q1 EBITDA MARGIN 27.17% VS 32.84% (YOY)

BLUE JET HEALTHCARE: Q1 REVENUE 1.62B RUPEES VS 1.79B (YOY)

BLUE JET HEALTHCARE: Q1 SL NET PROFIT 378M RUPEES VS 441M (YOY)

MOREPEN LABS: CO RAISES RUPEES 200 CR VIA QIP

LUPIN: CO GETS SHOW CAUSE NOTICE FROM MAHARASHTRA GST AUTHORITY SEEKING RECOVERY OF ₹672.4 CR OF TAX & PENALTY -- CO GETS SHOW CAUSE NOTICE FOR PERIOD JULY 2017 TO MARCH 2022

GLENMARK LIFE SCIENCES: CO SAYS STAKE OF PROMOTER IN CO REDUCED FROM 75.00073% TO 74.99982% -- CO HAS BECOME COMPLIANT WITH MINIMUM PUBLIC SHAREHOLDING REQUIREMENTS

STRIDES PHARMA SCIENCE: CO SAYS ACQUISITION OF BALANCE STAKE IN STRIDES GLOBAL CONSUMER HEALTHCARE

LUPIN: CO SAYS INCORPORATED LUPIN LANKA (PVY) LTD., SRI LANKA (‘LUPIN LANKA’), AS WHOLLY OWNED SUBSIDIARY OF THE CO

AUROBINDO PHARMA: CO SAYS US FDA INSPECTION AT UNIT II OF EUGIA PHARMA SPECIALITIES -- CO SAYS US FDA DETERMINED CLASSIFICATION STATUS OF FACILITY AS OFFICIAL ACTION INDICATED

BIOCON: CO HAS RECEIVED AN ESTABLISHMENT INSPECTION REPORT (EIR) WITH VOLUNTARY ACTION INDICATED (VAI) FROM THE U.S. FOOD AND DRUG ADMINISTRATION (USFDA), FOR OUR API FACILITY (SITE 5), LOCATED AT VISAKHAPATNAM, ANDHRA PRADESH

INDRAPRASTHA MEDICAL CORP: Q1 EBITDA 680M RUPEES VS 472M (YOY) -- Q1 EBITDA MARGIN 19.54% VS 15.43% (YOY)

INDRAPRASTHA MEDICAL CORP: Q1 SL NET PROFIT 448M RUPEES VS 305M (YOY) -- Q1 REVENUE 3.5B RUPEES VS 3.06B (YOY)

SMS PHARMA: Q1 EBITDA 335M RUPEES VS 262M (YOY) -- Q1 EBITDA MARGIN 20.38% VS 19.35% (YOY)

SMS PHARMA: Q1 REVENUE 1.64B RUPEES VS 1.35B (YOY)

SMS PHARMA: Q1 CONS NET PROFIT 165M RUPEES VS 93.4M (YOY)

ASTER DM: CO EYES BLACKSTONES CARE HOSPITAL FOR BED EXPANSION PLAN -- CO AND BLACKSTONE LOOKING AT SHARE SWAP TO CONCLUDE THIS DEAL - CNBC TV18

SPARC: Q1 SL NET LOSS 959M RUPEES VS LOSS 954M (YOY) -- Q1 REVENUE 168M RUPEES VS 240M (YOY)

VIJAYA DIAGNOSTIC CENTRE: Q1 EBITDA 612M RUPEES VS 481M (YOY) -- Q1 EBITDA MARGIN 39.20% VS 39.75% (YOY)

VIJAYA DIAGNOSTIC CENTRE: Q1 REVENUE 1.56B RUPEES VS 1.2B (YOY)

VIJAYA DIAGNOSTIC CENTRE: Q1 CONS NET PROFIT 313M RUPEES VS 262M (YOY)

SUVEN LIFE SCIENCES: Q1 SL NET LOSS 77M RUPEES VS LOSS 29M (YOY) -- Q1 REVENUE 10M RUPEES VS 38M (YOY)

JUBILANT PHARMOVA: RS 119.57CR NSE BLOCK TRADE; FOR ~1405000 SHARES, AT RS 851 (PRE-OPEN)

ERIS LIFESCIENCES: CO IS GIVING GUIDANCE OF 28% FOR THE BIOCON-2 PIECE AND OVERALL 33% FOR BOTH BIOCON PUT TOGETHER -- DBF SEGMENT IS EXPECTED TO HAVE A REVENUE OF RS 2,600-PLUS CR WITH AN EBITDA MARGIN OF 36% FOR THE YEAR - CONCALL UPDATE

ERIS LIFESCIENCES: CO EXPECTS A COMBINED REVENUE OF RS 280 CR FROM BASALOG AND INSUGEN, REPRESENTING A 40% GROWTH OVER THE ACQUIRED BASE - CONCALL UPDATE

ERIS LIFESCIENCES: COS GUIDANCE FOR THE ACQUIRED BUSINESS INCLUDES RS 125 CR REVENUE, REPRESENTING A 25% GROWTH ON THE ACQUIRED BASE, WITH AN EBITDA MARGIN OF 36% - CONCALL UPDATE

ERIS LIFESCIENCES: GUIDANCE FOR THE YEAR INCLUDES AN ORGANIC REVENUE GROWTH OF 12% TO 14% WITH AN EBITDA MARGIN OF 37% FOR THE BASE BUSINESS - CONCALL UPDATE

NARAYANA HRUDAYALAYA: Q1 EBITDA 3.3B RUPEES VS 2.86B (YOY) -- Q1 EBITDA MARGIN 24.41% VS 23.17% (YOY)

NARAYANA HRUDAYALAYA: Q1 CONS NET PROFIT 2B RUPEES VS 1.84B (YOY); 1.9B (QOQ) -- Q1 REVENUE 13.4B RUPEES VS 12.33B (YOY)

GLAND PHARMA: CO SAYS US FDA CONDUCTED UN-ANNOUNCED INSPECTION OF PASHAMYLARAM FACILITY; CONCLUSION OF US FDA UN-ANNOUNCED INSPECTION AT PASHAMYLARAM FACILITY, HYDERABAD -- CO SAYS INSPECTION WAS CONCLUDED WITH THREE (3) 483 OBSERVATIONS

GLAXOSMITHKLINE PHARMA: Q1 EBITDA 2.31B RUPEES VS 1.44B (YOY) -- Q1 EBITDA MARGIN 28.30% VS 18.89% (YOY)

GLAXOSMITHKLINE PHARMA: Q1 CONS NET PROFIT 1.82B RUPEES VS 1.3B (YOY); 1.94B (QOQ) -- Q1 REVENUE 8.15B RUPEES VS 7.6B (YOY); 9.3B (QOQ)

ERIS LIFESCIENCES: Q1 EBITDA 2.5B RUPEES VS 1.7B (YOY) -- Q1 EBITDA MARGIN 34.73% VS 36.38% (YOY)

ERIS LIFESCIENCES: Q1 REVENUE 7.2B RUPEES VS 4.6B (YOY)

ERIS LIFESCIENCES: Q1 CONS NET PROFIT 830M RUPEES VS 948M (YOY)

MARKSANS PHARMA: COS UNIT IN UK RELONCHEM LIMITED, RECEIVES MARKETING AUTHORIZATION FOR THE PRODUCT LEVONORGESTREL TABLETS FROM UK MHRA

HESTER BIOSCIENCES: Q1 EBITDA 176M RUPEES VS 144M (YOY) -- Q1 EBITDA MARGIN 21.4% VS 16.35% (YOY)

HESTER BIOSCIENCES: Q1 REVENUE 822M RUPEES VS 878M (YOY)

HESTER BIOSCIENCES: Q1 CONS NET PROFIT 63M RUPEES VS 59M (YOY)

ALEMBIC PHARMACEUTICALS: CO RECEIVES USFDA FINAL APPROVAL FOR NELARABINE INJECTION -- INJECTION HAS US SALES OF 23M USD

AUROBINDO PHARMA: COS RS 750 CRORE BUYBACK TO OPEN ON AUGUST 5, CLOSE ON AUGUST 9

INDEGENE: Q1 EBITDA 1.3B RUPEES VS 968M (YOY) -- Q1 EBITDA MARGIN 19.05% VS 15.93% (YOY)

INDEGENE: Q1 CONS NET PROFIT 877M RUPEES VS 684M (YOY); 948M (QOQ) -- Q1 REVENUE 6.8B RUPEES VS 6.1B (YOY)

MOREPEN LABORATORIES: CO SAYS AUTHORISED THE OPENING OF QIP ISSUE ON AUG 1 -- CO APPROVED FLOOR PRICE FOR QIP AT 57.23 RUPEES PER SHR

NEULAND LAB: COS R&D TEAM IS WORKING ON AN EXCITING SET OF MOLECULES TO ADD TO THEIR PORTFOLIO - INVESTOR PRESENTATION

NEULAN LAB: CO EXPECT THEIR BUSINESS TO REGAIN MOMENTUM FROM FY26 ONWARDS BASIS THEIR VISIBILITY FROM THEIR PORTFOLIO OF PROJECTS AND PRODUCTS - INVESTOR PRESENTATION

AARTI DRUGS: CO SAYS US FDA CONDUCTED INSPECTION AT UNITS MANUFACTURING FACILITY AT BADDI -- PINNACLE IS IN RECEIPT OF ESTABLISHMENT INSPECTION REPORT

NEULAND LABORATORIES: Q1 EBITDA 1.23B RUPEES VS 969M (YOY) -- Q1 EBITDA MARGIN 28.06% VS 26.70% (YOY)

NEULAND LABORATORIES: Q1 REVENUE 4.4B RUPEES VS 3.63B (YOY)

NEULAND LABORATORIES: Q1 CONS NET PROFIT 979M RUPEES VS 619M (YOY)

HIKAL: Q1 EBITDA 580M RUPEES VS 503M (YOY) -- Q1 EBITDA MARGIN 14.26% VS 12.96% (YOY)

HIKAL: Q1 REVENUE 4B RUPEES VS 3.9B (YOY)

HIKAL: Q1 CONS NET PROFIT 51M RUPEES VS 69M (YOY)

SUN PHARMA: COS US FORMULATION SALES AT USD 466M VS EST USD 518M

SUN PHARMA: COS US FORMULATION SALES AT USD 466M, LOWER BY 1%

SUN PHARMA INDUSTRIES: GLOBAL SPECIALTY SALES AT US$ 266 MILLION, EST $281M

SUN PHARMA INDUSTRIES: Q1 EBITDA 36.1B RUPEES VS 33.3B (YOY); EST 33.44B -- Q1 EBITDA MARGIN 28.51% VS 27.90% (YOY); EST 26%

SUN PHARMA INDUSTRIES: Q1 REVENUE 126.5B RUPEES VS 119.4B (YOY); EST 128.44B

SUN PHARMA INDUSTRIES: Q1 CONS NET PROFIT 28.4B RUPEES VS 20.2B (YOY); EST 25.89B

MAX HEALTHCARE INSTITUTE: Q1 REVENUE 15.4B RUPEES VS 12.85B (YOY)

MAX HEALTHCARE INSTITUTE: Q1 EBITDA 3.87B RUPEES VS 3.37B (YOY) -- Q1 EBITDA MARGIN 25.11% VS 26.26% (YOY)

MAX HEALTHCARE INSTITUTE: Q1 CONS NET PROFIT 2.4B RUPEES VS 2.40B (YOY)

MANKIND PHARMA LTD: RS. 68.88 CRORES NSE BLOCK TRADE; FOR ~ 345740 SHARES, AT RS. 1992.25

MANKIND PHARMA: CO EXPECTS 15% TO 20% GROWTH, WITH POTENTIAL FOR EVEN BETTER PERFORMANCE -- CO TARGETS MARGINS AROUND 30% PLUS, WITH YEAR-OVER-YEAR IMPROVEMENT - CONCALL UPDATE

ASTER DM HEALTHCARE: Q1 EBITDA 1.6B RUPEES VS 1.2B (YOY) -- Q1 EBITDA MARGIN 16.17% VS 14.51% (YOY)

ASTER DM HEALTHCARE: Q1 CONS NET PROFIT FROM CONTINUING OPS 810M RUPEES VS 447M (YOY); 418M (QOQ) -- Q1 REVENUE 10B RUPEES VS 8.4B (YOY)

APOLLO HOSPITAL: CO TO CONSIDER Q1 RESULT ON AUG 13

MANKIND PHARMA: Q1 EBITDA 6.8B RUPEES VS 6.55B (YOY)

MANKIND PHARMA: Q1 REVENUE 29B RUPEES VS 25.79B (YOY)

MANKIND PHARMA: Q1 CONS NET PROFIT 5.4B RUPEES VS 4.87B (YOY)

SOLARA ACTIVE PHARMA SCIENCES: CO SAYS COMPLETION OF EU GMP INSPECTION AT PUDUCHERRY FACILITY -- AGENCY ISSUED FORMAL EU GMP CERTIFICATE

KOPRAN: CO HAS RECEIVED ENVIRONMENTAL CLEARANCE FROM GOVERNMENT OF INDIA -- CO WILL NOW OBTAIN CONSENT TO ESTABLISH (CTE) AND CONSENT TO OPERATE (CCA) FROM GUJARAT POLLUTION CONTROL BOARD

SHILPA MEDICARE: CO UNIT SHILPA PHARMA LIFESCIENCES, RECEIVED CEP FROM EDQM FOR API, URSODEOXYCHOLIC ACID

ZYDUS LIFE: CO RECEIVES APPROVAL FROM COFEPRIS OF MEXICO TO MARKET MAMITRA (TRASTUZUMAB BIOSIMILAR) TO TREAT VARIOUS CANCERS

DR. LAL PATH LABS: CO TO CONSIDER Q1 RESULTS ON AUG 7

DIVIS LAB: AGROCHEM & PHARMA MONTHLY DATA OUT -- MONTHLY DATA AT $39MN, INDICATING 55% (MOM) DROP & 56% (YOY) DROP

AJANTA PHARMA: CO EXPECTS OVERALL REVENUE TO GROW IN LOW TEENS IN FY 2025 -- CO EXPECTS MID-TEEN GROWTH IN BRANDED GENERICS AND DE-GROWTH IN AFRICA INSTITUTION BUSINESS IN FY 2025 - CONCALL UPDATE

GRANULES INDIA: CO IS GUIDING FOR A SIGNIFICANT IMPACT FROM THE DOMINANCE OF ITS METFORMIN PRODUCT IN THE DIABETES SEGMENT.-- CO IS ON TRACK WITH ITS CAPITAL EXPENDITURE PLANS AND EXPECTS TO BE IN LINE WITH ITS ESTIMATES AND EXPECTATIONS - CONCALL UPDATE

GRANULES INDIA: CO EXPECTS TO SEE AN IMPROVING TRAJECTORY IN ITS FINANCIAL PERFORMANCE, CO EXPECTS TO CONTRIBUTE SIGNIFICANTLY TO ITS ENTIRE PORTFOLIO FROM FY 26 ONWARDS, DRIVEN BY THE LAUNCH OF ONCOLOGY PRODUCTS - CONCALL UPDATE

DR REDDYS LAB: BARCLAYS RAISES TARGET PRICE TO $87 FROM $81

PIRAMAL PHARMA: CO TO SELL PLOT OF LAND, FACTORY FOR ABOUT 90 MLN RUPEES

AJANTA PHARMA: Q1 REVENUE 11.5B RUPEES VS 10.21B (YOY)

AJANTA PHARMA: Q1 EBITDA 3.3B RUPEES VS 2.71B (YOY) -- Q1 EBITDA MARGIN 29% VS 26.53% (YOY)

AJANTA PHARMA: Q1 CONS NET PROFIT 2.5B RUPEES VS 2.08B (YOY)

GRANULES INDIA : CO MD SAYS Q1 PERFORMANCE HIGHLIGHTS INCLUDE CONTINUED GROWTH IN OUR FORMULATION SEGMENT, STRONG NORTH AMERICA BUSINESS, AND PRODUCT DIVERSIFICATION, WHICH OFFSET THE PARACETAMOL API/PFI DECLINE, PROMISING A BRIGHTER FUTURE DRIVEN BY OUR FORMULATIONS OFFERING AND NEW PRODUCT PIPELINE

GRANULES INDIA: Q1 EBITDA 2.59B RUPEES VS 1.37B (YOY) -- Q1 EBITDA MARGIN 21.97% VS 13.88% (YOY)

GRANULES INDIA: Q1 REVENUE 11.8B RUPEES VS 9.85B (YOY)

GRANULES INDIA: Q1 CONS NET PROFIT 1.35B RUPEES VS 479M (YOY)

STRIDES PHARMA: CO EXPECTS TO REDUCE ITS NET DEBT TO EBITDA RATIO TO LESS THAN 2X BY THE END OF THE YEAR -- CO EXPECTS ITS OPERATING COST TO REVENUE RATIO TO IMPROVE IN TANDEM WITH GROWTH IN H2 - CONCALL UPDATE

PFIZER: Q1 EBITDA 1.8B RUPEES VS 1.11B (YOY) -- Q1 EBITDA MARGIN 31.62% VS 20.90% (YOY)

PFIZER: Q1 REVENUE 5.6B RUPEES VS 5.31B (YOY)

PFIZER: Q1 SL NET PROFIT 1.5B RUPEES VS 935M (YOY); 1.8B (QOQ)

AARTI DRUGS: CO SAYS US FDA EIR AT MANUFACTURING FACILITY OF UNIT AT BADDI, HIMACHAL PRADESH -- CO GETS EIR FROM USFDA CONCLUDING INSPECTION AS CLOSED

SASTASUNDAR VENTURES: Q1 REVENUE 2.7B RUPEES VS 3.36B (YOY)

SASTASUNDAR VENTURES: Q1 CONS NET PROFIT 312M RUPEES VS 13M (YOY)

STRIDES PHARMA: COS ONESOURCE FY25 OUTLOOK: AIMING FOR EBITDA IN RANGE OF USD 60-65M

STRIDES PHARMA: COS ONESOURCE FY25 OUTLOOK: COS AIMING FOR REVENUE IN RANGE OF USD 175-190M

STRIDES PHARMA: CO AIMING FOR NET DEBT REDUCTION OF RS 5,000M (INCLUDING DEBT PUSHDOWN OF RS 2,800M TO ONESOURCE)

STRIDES PHARMA SCIENCE: CO MD SAYS OUR EMPHASIS ON PROFITABILITY, EFFICIENCY AND GROWTH HAS LED TO A STRONG PERFORMANCE ACROSS MARKETS, ALLOWING US TO DELIVER SUPERIOR RETURNS AHEAD OF THE PROJECTED TIMELINES FOR OUR FY25 OUTLOOK

STRIDES PHARMA SCIENCE: Q1 CONS NET PROFIT 683M RUPEES VS LOSS 94M (YOY)

MANKIND PHARMA LTD: RS. 78.13 CRORES NSE BLOCK TRADE; FOR ~ 378709 SHARES, AT RS. 2063.10

DR REDDYS: CO RECEIVES POSITIVE CHMP OPINION FROM EUROPEAN MEDICINES AGENCY FOR RITUXIMAB BIOSIMILAR

DR REDDYS LAB: CO IS INVESTING IN ITS BIOSIMILAR PRODUCTS PIPELINE DEVELOPMENT EFFORTS, INCLUDING GENERIC AND NOVEL ONCOLOGY ASSETS - CONCALL UPDATE

DR REDDYS LAB: CO EXPECTS THE NORMAL EFFECTIVE TAX RATE TO BE IN THE RANGE OF 24% TO 25% FOR THE FISCAL -- CO IS DEVELOPING INNOVATIVE SOLUTIONS THROUGH PARTNERSHIPS AND COLLABORATIONS.- CONCALL UPDATE

DR REDDYS LAB: CO EXPECTS SG&A TO BE IN THE RANGE OF 27.5% TO 28% FOR THE FULL FISCAL -- CO EXPECTS R&D INVESTMENT TO BE IN THE RANGE OF 8.5% TO 9% FOR THE FULL FISCAL - CONCALL UPDATE

GLENMARK LIFE: CO IS EXPECTING A NUMBER OF APPROVALS ON NEW PRODUCTS AND AN EXPANSION BASKET WITH MORE MARKETS GETTING ADDED TO RECENT LAUNCHES - CONCALL UPDATE

GLENMARK LIFE: CO SAYS FOUR PRODUCTS HAVE ALREADY BEEN VALIDATED, AND FOUR ARE IN ADVANCED STAGES OF DEVELOPMENT -- CO ALSO SAYS NEW LAUNCHES ARE FORESEEN TO COME UP NEXT YEAR AND IN EARLY FY 27 - CONCALL UPDATE

GLENMARK LIFE: CO SAYS THE SOLAPUR PROJECT IS EXPECTED TO BE COMPLETED IN 18-20 MONTHS, WITH PHASE 1 TAKING UP THIS FINANCIAL YEAR AND NEXT - CONCALL UPDATE

GLENMARK LIFE: CO EXPECTS TO ADD ANOTHER RS 100 CRORES TO ITS CDMO BUSINESS BY MID-NEXT YEAR, ON TOP OF THE CURRENT RS 140 CRORES TO RS 150 CRORE - CONCALL UPDATE

GLENMARK LIFE: CO GUIDED TO CDMO BEING RS 500 CRORE TO RS 600 CRORE IN THE NEXT 4 YEARS - CONCALL UPDATE

DR. REDDYS LAB: CO TO INVEST GBP 500M OR RUPEES 51.31B IN UNIT FOR NICOTINELL ACQUISITION

DR. REDDYS LAB: CO APPROVED SUB-DIVISION/ SPLIT OF EQUITY SHARES IN RATIO OF 1: 5 (1 EXISTING SHARE SPLIT INTO 5 NEW SHARES)

DR.REDDYS LAB: Q1 EBITDA 21.6B RUPEES VS 21.37B (YOY); EST 19.72B -- Q1 EBITDA MARGIN 28.2% VS 31.7% (YOY); EST 27.4% - AS PER CO STATEMENT

DR.REDDYS LAB: Q1 CONS NET PROFIT 13.92B RUPEES VS 14.02B (YOY); EST 13.35B -- Q1 REVENUE 76.96B RUPEES VS 67.58B (YOY); EST 71.83B

INDOCO REMEDIES: CO RECEIVED 7 OBSERVATIONS IN FORM 483 ON CONCLUSION OF THE INSPECTION BY USFDA AT GOA FACILITY

THEMIS MEDICARE: CO PROJECTS 35% CAGR OVER NEXT 3 YEARS WHILE MAINTAINING EBITDA ABOVE 25% - INVESTOR PRESENTATION

THEMIS MEDICARE: CO SAYS TRANSFER OF THE API BUSINESS TO UNIT IS UNDERWAY -- CO SAYS WILL FURTHER HELP STREAMLINE OPERATIONS, THEREBY FACILITATING BETTER STRATEGY IMPLEMENTATION FOR FUTURE GROWTH IN BOTH BUSINESSES - INVESTOR PRESENTATION

THEMIS MEDICARE: CO EXPANDS TRADE BUSINESS WITH RAPID GROWTH IN PHARMA SEGMENT AND UPCOMING GENERIC LAUNCHES - INVESTOR PRESENTATION

STRIDES PHARMA: CO SAYS STRIDES NEW ZEALAND SHALL HOLD MARKET AUTHORIZATIONS FOR THE PRODUCTS IN NEW ZEALAND AND SHALL ALSO UNDERTAKE TRADING IN PHARMACEUTICAL PRODUCTS

STRIDES PHARMA: CO HAS INCORPORATED CO IN NEW ZEALAND IN THE NAME OF STRIDES PHARMA NEW ZEALAND PTY LTD

GLENMARK LIFE SCIENCES: CO SAYS GUJARAT POLLUTION CONTROL BOARD (GPCB) ISSUES CLOSURE NOTICE FOR CO’S ANKLESHWAR FACILITY

AARTI DRUGS: CO SAYS THE GUJARAT SAYAKHA GREENFIELD PROJECT FOR SPECIALTY CHEMICALS IS ON TRACK TO BEGIN BY THE END OF Q2 FY25, WITH THIS OPERATING LEVERAGE EXPECTED TO ENHANCE CAPACITY UTILIZATION FROM THE SECOND HALF OF THE YEAR - INVESTOR PRESENTATION

AARTI DRUGS: CO SAYS IN FY25, ANTICIPATE IMPROVEMENT IN MARGINS DRIVEN BY GROWTH IN EXPORT SALES -- CO SAYS ANTICIPATE TOTAL CAPEX OF 2B RUPEES FOR FY25

THEMIS MEDICARE: Q1 EBITDA 292M RUPEES VS 114M (YOY) -- Q1 EBITDA MARGIN 27.56% VS 16.50% (YOY)

THEMIS MEDICARE: Q1 REVENUE 1.06B RUPEES VS 693M (YOY)

THEMIS MEDICARE: Q1 SL NET PROFIT FROM CONTINUING OPERATION 203M RUPEES VS 68M (YOY); 42M (QOQ)

AARTI DRUGS: Q1 EBITDA 650M RUPEES VS 841M (YOY) -- Q1 EBITDA MARGIN 11.70% VS 12.72% (YOY)

AARTI DRUGS: Q1 REVENUE 5.6B RUPEES VS 6.61B (YOY)

AARTI DRUGS: Q1 CONS NET PROFIT 332M RUPEES VS 478M (YOY); 474M (QOQ)

SANOFI INDIA: CO HAS EXCEPTIONAL ITEM OF LOSS 190M RUPEES -- Q1 PBT 1.11B RUPEES VS 1.27B (YOY)

SANOFI INDIA: Q1 EBITDA 1.16B RUPEES VS 1.23B (YOY) -- Q1 EBITDA MARGIN 24.96% VS 23.62% (YOY)

SANOFI INDIA: Q1 REVENUE 4.64B RUPEES VS 5.15B (YOY); 5.11B (QOQ)

SANOFI INDIA: Q1 SL NET PROFIT 1.03B RUPEES VS 1.23B (YOY); 1.37B (QOQ)

CIPLA: COS SOUTH AFRICA: MOMENTUM CONTINUES WITH REVENUE GROWTH AT 19% IN LOCAL CURRENCY TERMS -- CO SAYS PRESCRIPTION BUSINESS RANKED 1 IN THE MARKET

CIPLA: COS NORTH AMERICA: ALL-TIME HIGH REVENUE AT USD 250M UP BY 13% YOY SUPPORTED BY TRACTION IN DIFFERENTIATED PORTFOLIO

CIPLA: Q1 EBITDA 17.2B RUPEES VS 14.94B (YOY); EST 16.13B -- Q1 EBITDA MARGIN 25.63% VS 23.60% (YOY); EST 23.8%

CIPLA: Q1 REVENUE 67B RUPEES VS 63.28B (YOY); EST 67.74B

CIPLA: Q1 CONS NET PROFIT 11.8B RUPEES VS 9.95B (YOY); EST 10.87B

ALEMBIC PHARMA: CO SAYS GMP INSPECTION AT PANELAV FACILITY WAS SUCCESSFULLY COMPLETED WITHOUT ANY FORM 483 OBSERVATION

PIRAMAL PHARMA: CO CHAIRPERSON SAYS IN CHG BUSINESS, PLANNED EXPANSION FOR INHALATION ANESTHESIA PORTFOLIO IS ON TRACK AND IS EXPECTED TO GET COMMERCIALIZED IN FY26

PIRAMAL PHARMA: Q1 EBITDA 2.24B RUPEES VS 1.71B (YOY) -- Q1 EBITDA MARGIN 11% VS 10% (YOY) (AS PER CO STATEMENT)

PIRAMAL PHARMA: Q1 CONS NET LOSS 886M RUPEES VS LOSS 986M (YOY) -- Q1 REVENUE 19B RUPEES VS 17.5B (YOY)

PIRAMAL PHARMA: Q1 EBITDA 1.51B RUPEES VS 165M (YOY) -- Q1 EBITDA MARGIN 14.26% VS 1.96% (YOY)

PIRAMAL PHARMA: Q1 REVENUE 10.6B RUPEES VS 8.46B (YOY)

PIRAMAL PHARMA: Q1 SL NET PROFIT 850M RUPEES VS LOSS 333.6M (YOY)

MANKIND PHARMA LTD: RS. 62.55 CRORES NSE BLOCK TRADE; FOR ~ 301966 SHARES, AT RS. 2071.30

LAURUS LABS: CO EXPECTS FY 25 TO BE A GOOD YEAR, WITH FY 26 EXPECTED TO BE EVEN BETTER DUE TO INVESTMENTS IN AREAS LIKE ANIMAL HEALTH STARTING TO YIELD RESULTS - CONCALL UPDATE

LAURUS LABS: CO EXPECTS AN IMPROVEMENT IN EBITDA IN THE SECOND HALF OF THE YEAR -- CO IS TARGETING A NET DEBT TO EBITDA RATIO OF LESS THAN 2.5X BY THE END OF MARCH 25 - CONCALL UPDATE

LAURUS LABS: CO REMAINS COMMITTED TO A HEALTHY GROWTH OUTLOOK FOR THE FULL YEAR, SUPPORTED BY SCHEDULED PROJECT DELIVERIES FOR KEY LATE-PHASE NCE PROJECTS IN Q4 OF THIS FINANCIAL YEAR - CONCALL UPDATE

SUN PHARMA: COS LEQSELVI (DEURUXOLITINIB) RECEIVES U.S. FDA APPROVAL FOR SEVERE ALOPECIA AREATA; ACHIEVES SIGNIFICANT EFFICACY IN PHASE 3 TRIALS

MANKIND PHARMA: CO TO ACQUIRE 100% STAKE IN BHARAT SERUMS AND VACCINES (BSV), FOR AN ENTERPRISE VALUE OF APPROX 136.3B RUPEES -- CO EXPANDS HIGH ENTRY BARRIER PORTFOLIO; LEADERSHIP IN WOMEN’S HEALTH

GLENMARK LIFE: CO ANTICIPATE DELIVERING STEADY GROWTH WITH STABLE MARGINS THROUGHOUT FY25 - INVESTOR PRESENTATION

GLENMARK LIFE: CO SAYS ANKLESHWAR CAPACITY EXPANSION CONSTRUCTION COMPLETED, TO BE OPERATIONAL IN Q2FY25

GLENMARK LIFE: CO SAYS ANTICIPATE DELIVERING STEADY GROWTH WITH STABLE MARGINS THROUGHOUT FY25 -- OPTIMISTIC ABOUT MAINTAINING GROWTH MOMENTUM FOR REST OF YEAR

GLENMARK LIFE SCIENCES: Q1 EBITDA 1.6B RUPEES VS 1.9B (YOY) -- Q1 EBITDA MARGIN 27.10% VS 33.38% (YOY)

GLENMARK LIFE SCIENCES: Q1 REVENUE 5.9B RUPEES VS 5.8B (YOY)

GLENMARK LIFE SCIENCES: Q1 SL NET PROFIT 1.1B RUPEES VS 1.35B (YOY); 979M (QOQ)

LAURUS LABS: CO CFO SAYS WE REMAIN COMMITTED TO FY2025 OUTLOOK AND OUR KEY CAPEX PROJECTS INTO HIGH VALUE BUSINESS SEGMENTS IS ADVANCING WELL TO DRIVE MEDIUM AND LONG TERM GROWTH

LAURUS LABS: CO CFO SAYS WE EXPECT PERFORMANCE TO PICK UP MOSTLY FROM H2, SUPPORTED BY ON HAND PROJECT DELIVERIES

LAURUS LABS: Q1 EBITDA 1.71B RUPEES VS 1.67B (YOY); EST 2.54B -- Q1 EBITDA ARGIN 14.33% VS 14.11% (YOY); EST 17.5%

LAURUS LABS: Q1 REVENUE 11.9B RUPEES VS 11.8B (YOY); EST 14.59B

LAURUS LABS: Q1 CONS NET PROFIT 125M RUPEES VS 248M (YOY); EST 913M

GLENMARK LIFE: ISSUE OF CLOSURE NOTICE FOR OUR ANKLESHWAR FACILITY BY GPCB -- GPCB ORDERED NOT TO CARRY PRODUCTION AT ANKLESHWAR FACILITY

GLAND PHARMA: CO SAYS INSPECTION WAS CONCLUDED WITH TWO (2) 483 OBSERVATIONS AT CO’S DUNDIGAL FACILITY

POLY MEDICURE: CO IS MANUFACTURING A PRODUCT IN INDIA AND WILL BE TRAINING THE SALES TEAM ON THE PRODUCT LINE INITIALLY, BUT THE BUSINESS WILL BE MANAGED LOCALLY BY THE PARTNER - CONCALL UPDATE

POLY MEDICURE: CO PLANS TO DEPLOY PART OF ITS FUNDS INTO INORGANIC OPPORTUNITIES TO ENHANCE TECHNOLOGY AND SHORTEN THE PRODUCT DEVELOPMENT CYCLE - CONCALL UPDATE

POLY MEDICURE: CO WILL USE AI-BASED TOOLS TO CONDUCT TRAINING PROGRAMS FOR INTERNATIONAL CLIENTS, NURSES, AND DOCTOR - CONCALL UPDATE

POLY MEDICURE: CO CONTINUES TO GUIDE 22% TO 24% REVENUE GROWTH FOR FY 25 AND 100-200 BPS MARGIN IMPROVEMENT OVER THIS CURRENT FINANCIAL YEAR - CONCALL UPDATE

POLY MEDICURE: CO IS ON TRACK TO PERFORM THIS YEAR AS PER THE GUIDANCE GIVEN EARLIER OF 22% TO 24% GROWTH, AND ALSO IMPROVEMENT IN THE EBITDA MARGIN OF 250 BPS - CONCALL UPDATE

SUN PHARMA: CO SAYS ADDITIONAL INFORMATION ON DADRA FACILITY RECEIVES WARNING LETTER FROM USFDA -- CO SAYS THERE IS NO IMPACT ON COS FINANCIAL, OPERATIONS, OR OTHER ACTIVITIES

SYNGENE INTERNATIONAL: CO MD SAYS BASED ON THE CURRENT DYNAMICS, WE ARE ON TRACK TO HIT OUR GUIDANCE RANGE FOR THE YEAR WITH MOMENTUM EXPECTED TO BUILD IN THE SECOND HALF OF THE YEAR

SYNGENE INTERNATIONAL: Q1 PROFIT BEFORE TAX AND EXCEPDONAL ITEMS 693M RS VS 1.23B (YOY) -- CO HAS AN EXCEPTIONAL ITEM OF 320M RS

SYNGENE INTERNATIONAL: Q1 EBITDA 1.69B RUPEES VS 2.11B (YOY) -- Q1 EBITDA MARGIN 21.50% VS 26.22% (YOY)

SYNGENE INTERNATIONAL: Q1 REVENUE 7.9B RUPEES VS 7.16B (YOY)

SYNGENE INTERNATIONAL: Q1 CONS NET PROFIT 757M RUPEES VS 934M (YOY)

BLISS GVS PHARMA: Q1 EBITDA 343M RUPEES VS 242M (YOY) -- Q1 EBITDA MARGIN 18.69% VS 15.18% (YOY)

BLISS GVS PHARMA: Q1 REVENUE 1.8B RUPEES VS 1.59B (YOY)

BLISS GVS PHARMA: Q1 CONS NET PROFIT 207M RUPEES VS 147M (YOY)

ALEMBIC PHARMACEUTICALS: CO RECEIVES USFDA FINAL APPROVAL FOR FLUPHENAZINE HYDROCHLORIDE TABLETS

IPCA LAB: CO TO CONSIDER Q1 RESULTS ON AUG 13

MANKIND PHARMA LTD: RS. 63.69 CRORES NSE BLOCK TRADE; FOR ~ 304720 SHARES, AT RS. 2090.15

TORRENT PHARMA: CO IS LOOKING TO ADD ONE MORE PRODUCT TO ITS PORTFOLIO TOWARDS THE END OF THE YEAR -- NEW PRODUCT LAUNCHES ARE EXPECTED IN THE US OVER THE NEXT TWO TO THREE YEARS, WHICH SHOULD DRIVE POSITIVELY TO THE OVERALL PERFORMANCE OF THE CO - CONCALL UPDATE

TORRENT PHARMA: CO PLANS TO LAUNCH FIVE PRODUCTS IN BRAZIL DURING THE REST OF THE YEAR AND INTENDS TO MAINTAIN THREE TO SIX LAUNCHES PER YEAR - CONCALL UPDATE

TORRENT PHARMA: CO EXPECTS 5-10 APPROVALS THIS YEAR, WHICH WOULD DRIVE SALES GROWTH -- CO EXPECTS A HIGHER RATE OF APPROVALS NEXT YEAR ONWARDS -- GUIDANCE GIVEN HOLDS TRUE, AND MARGIN IMPROVEMENT IS EXPECTED TO HAPPEN ON A FULL-YEAR BASIS - CONCALL UPDATE

KRSNAA DIAGNOSTICS: CO HAS RECEIVED THE SIGNED AGREEMENT FROM THE GOVT OF MADHYA PRADESH FOR SETTING UP, OPERATING, MANAGING & MAINTAINING OF MRI SCAN (1.5 TESLA) MACHINES AT 5 (FIVE) DISTRICT HOSPITALS OF MADHYA PRADESH NAMELY BHOPAL, INDORE, UJJAIN, GWALIOR & JABALPUR RESPECTIVELY

SUVEN PHARMA: CO GETS OBSERVATION LETTER WITH NO ADVERSE OBSERVATIONS FROM BSE AND NO OBSERVATIONS FROM NSE -- OBSERVATIONS FOR SCHEME OF AMALGAMATION SEEKING AMALGAMATION OF COHANCE LIFESCIENCES WITH CO

PIRAMAL PHARMA: CO TO ENTER INTO AGREEMENTS WITH CLEAN MAX AERO, CLEAN MAX ENVIRO ENERGY SOLUTIONS -- DEAL FOR 21.6M RUPEES

DR REDDYS LAB: BOARD MEETING ON JULY 27 TO CONSIDER SUB-DIVISION/ SPLIT OF EXISTING SHARES

KIMS: CO RECEIVED INTIMATION ABOUT THE PROPOSED MERGER OF RAJYALAKSHMI HEALTHCARE PRIVATE A STEP DOWN SUBSIDIARY OF CO WITH ITS HOLDING CO, SARVEJANA HEALTHCARE PRIVATE LIMITED, HAS BEEN APPROVED

TORRENT PHARMACEUTICALS: Q1 EBITDA 9B RUPEES VS 7.91B (YOY) -- Q1 EBITDA MARGIN 31.62% VS 30.53% (YOY)

TORRENT PHARMACEUTICALS: Q1 REVENUE 28.6B RUPEES VS 25.91B (YOY)

TORRENT PHARMACEUTICALS: Q1 CONS NET PROFIT 4.6b RUPEES VS 3.78B (YOY)

SHILPA MEDICARE: CO UNIT SHILPA PHARMA LIFESCIENCES, UNIT 2 CLEARED COFEPRIS-MEXICO GMP INSPECTION -- CO UNIT ISSUED GMP CERTIFICATION FROM COFEPRIS-MEXICO

IOL CHEMICALS AND PHARMACEUTICALS: CO SAYS THIS CERTIFICATION WILL ENABLE THE CO TO EXPORT THIS PRODUCT IN EUROPEAN AND OTHER CEP ACCEPTING COUNTRIES -- VALSARTAN IS USED FOR TO TREAT HIGH BLOOD PRESSURE (HYPERTENSION)

IOL CHEMICALS AND PHARMACEUTICALS: CO SAYS EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTH CARE (EDQM) HAS ISSUED A CERTIFICATE OF SUITABILITY FOR “VALSARTAN”

THYROCARE TECHNOLOGIES: Q1 EBITDA 426.4M RUPEES VS 345M (YOY) -- Q1 EBITDA MARGIN 27.17% VS 25.58% (YOY)

THYROCARE TECHNOLOGIES: Q1 REVENUE 1.57B RUPEES VS 1.35B (YOY)

THYROCARE TECHNOLOGIES: Q1 CONS NET PROFIT 241.7M RUPEES VS 173M (YOY)

GLAND PHARMA: CO RECEIVES TENTATIVE APPROVAL FROM THE USFDA FOR LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION -- SOLUTION HAS US SALES OF APPROXIMATELY USD 153 MILLION

GLOBAL HEALTH: CO SECURES MHADA LAND PARCEL IN MUMBAI FOR RUPEES 125.11 CR

ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM USFDA FOR VALSARTAN TABLETS

CIPLA LTD: Rs. 30.12 Crores NSE Block Trade; for ~ 201578 Shares, at Rs. 1494.00

SOLARA ACTIVE PHARMA: CO REAFFIRMED ITS GUIDANCE FOR THE FULL YEAR. REVENUE GUIDANCE IS IN THE RANGE OF RUPES 1,400 CRORES TO RUPEES 1,500 CRORES -- CO HAS PROVIDED GUIDANCE FOR EBITDA, EXPECTING TO REACH 20% TO 22%, WHICH IS ALMOST A HISTORICAL HIGH. - CONCALL UPDATE

PFIZER: BOARD MEETING ON JULY 29 TO CONSIDER Q1 RESULTS

SOLARA ACTIVE PHARMA SCIENCES: Q1 REVENUE 3.63B RUPEES VS 3.52B (YOY)

SOLARA ACTIVE PHARMA SCIENCES: Q1 EBITDA 419M RUPEES VS 200M (YOY) -- Q1 EBITDA MARGIN 11.5% VS 5.68% (YOY)

SOLARA ACTIVE PHARMA SCIENCES: CO REAFFIRMS FY25 GUIDANCE OF REVENUE ~INR 15,000 MN & THE FULL YEAR EBITDA ~INR. 2,300 TO 2,600 MN WITH Q4’25 EXIT QUARTER REVENUE ~ INR. 4,000 MN & EBITDA OF ~INR 800 TO INR 900 MN (EBITDA MARGINS OF 20-22

SOLARA ACTIVE PHARMA SCIENCES: CO SAYS OUR NET DEBT TO EBITDA GUIDANCE IS ~3 TIMES BY Q4’25. THE COMPANY IS CONFIDENT OF BEATING THE NET DEBT TO EBITDA GUIDANCE.

SOLARA ACTIVE PHARMA SCIENCES: Q1 CONS NET LOSS 135M RUPEES VS LOSS 196M (YOY)

POLY MEDICURE: Q1 REVENUE 3.85B RUPEES VS 3.2B (YOY)

POLY MEDICURE: Q1 EBITDA 1B RUPEES VS 872M (YOY) -- Q1 EBITDA MARGIN 27.54% VS 27.18% (YOY)

POLY MEDICURE: Q1 CONS NET PROFIT 740M RUPEES VS 627M (YOY)

ZYDUS LIFE: RS 124.29CR BSE BLOCK TRADE; FOR ~1075533 SHARES, AT RS 1155.65

MANKIND PHARMA LTD: Rs. 47.24 Crores NSE Block Trade; for ~ 223388 Shares, at Rs. 2114.70

ZYDUS LIFE: CO RECEIVES APPROVAL FROM COFEPRIS OF MEXICO TO MARKET  BHAVA™ (BEVACIZUMAB BIOSIMILAR) TO TREAT VARIOUS CANCERS

ASTER DM HEALTHCARE: CO UNIT MALABAR INSTITUTE OF MEDICAL SCIENCES TO ACQUIRE 25% STAKE IN USOLAR ASSETCO -- COST OF ACQUISITION 78.8M RUPEES

RPG LIFE SCIENCES: Q1 EBITDA 391M RUPEES VS 322M (YOY) -- Q1 EBITDA MARGIN 23.62% VS 21.82% (YOY)

RPG LIFE SCIENCES: Q1 REVENUE 1.65B RUPEES VS 1.48B (YOY)

RPG LIFE SCIENCES: Q1 SL NET PROFIT 268M RUPEES VS 221M (YOY)

ZYDUS LIFE: CO IS CONFIDENT OF ADDRESSING FDA ISSUES WITHIN TIMELINE

ZYDUS LIFE: CO SAYS USFDA CONDUCTED AN INSPECTION AT THE GROUP’S TRANSDERMAL MANUFACTURING SITE LOCATED AT SEZ IN AHMEDABAD -- THE INSPECTION CLOSED WITH 2 OBSERVATIONS

JUBILANT PHARMOVA: Q1 REVENUE 17.2B RUPEES VS 15.66B (YOY)

JUBILANT PHARMOVA: Q1 CONS NET PROFIT 4.8B RUPEES VS 64M (YOY) -- CO HAS ONE TIME EXCEPTIONAL GAIN OF 3.96B

JUBILANT PHARMOVA: Q1 CONS NET PROFIT BEFORE EXCEPTIONAL ITEM 1.03B RUPEES VS 266M (YOY) -- CO HAS AN EXCEPTIONAL ITEM OF 3.9B RUPEES

JUBILANT PHARMOVA: Q1 EBITDA 2.5B RUPEES VS 1.7B (YOY) -- Q1 EBITDA MARGIN 14.52% VS 10.69%(YOY)

DIVIS LAB: CO SAYS USFDA INSPECTION IS SUCEESFULLY COMPLETED WITH ONE PROCEDURAL OBSERVATION AT ANDHRA PLANT

ZYDUS LIFESCIENCES: CO RECEIVES FINAL APPROVAL FROM USFDA FOR NDA ZITUVIMETTM XR (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE) EXTENDED-RELEASE TABLETS -- TABLETS HAS US SALES HAS US SALES OF APPROX 9.5B USD

CAPLIN POINT LABS: CAPLIN STERILES GETS USFDA APPROVAL FOR EPHEDRINE SULFATE INJECTION USP

GLOBAL HEALTH LTD: Rs. 29.18 Crores NSE Block Trade; for ~ 242359 Shares, at Rs. 1204.15

ZYDUS LIFESCIENCES: CO GUJARAT PLANT RECEIVES OFFICIAL ACTION INDICATED NOTICE FROM USFDA

DR. REDDY’S LAB: CO SIGNS NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDA TO COMMERCIALISE VONOPRAZAN, A NOVEL GASTROINTESTINAL DRUG, IN INDIA

CIPLA LTD: Rs. 37.91 Crores NSE Block Trade; for ~ 251497 Shares, at Rs. 1507.45

AUROBINDO PHARMA: CO FIXES JULY 30, 2024 AS RECORD DATE FOR SHARE BUYBACK

AUROBINDO PHARMA: CO APPROVED SHARE BUYBACK AT THE PRICE OF RUPEES 1460 VIA TENDER OFFER ROUTE

VIMTA LABS: CO TARGETS RUPEES 500 CR REVENUE BY FY26: NEW LIFESCIENCES CAPACITY TO DRIVE FUTURE GROWTH -- SLIGHT QOQ IMPROVEMENT WITH 30.6% OPM - INVESTOR PRESENTATION

VIMTA LABS: Q1 EBITDA 245.2M RUPEES VS 247M (YOY) -- Q1 EBITDA MARGIN 29.99% VS 29.53% (YOY)

VIMTA LABS: Q1 REVENUE 817.6M RUPEES VS 835M (YOY)

VIMTA LABS: Q1 CONS NET PROFIT 122.8M RUPEES VS 122M (YOY)

AARTI DRUGS: CO SAYS RECEIVED AN ORDER FROM MAHARASHTRA POLLUTION CONTROL BOARD (MPCB) ISSUING VOLUNTARY CLOSURE DIRECTIONS OF MANUFACTURING ACTIVITY OF PARTICULAR PRODUCT AT T-150 UNIT LOCATED AT TARAPUR, MAHARASHTRA

SANOFI INDIA: CO ANNOUNCES EXPANSION OF ITS GLOBAL CAPACITY CENTRE IN HYDERABAD -- CO PLANS EURO 400M INVESTMENT BY 2030, WITH EURO 100M BY 2025 - RTRS

ZYDUS LIFESCIENCES: ZYDUS ANNOUNCES NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDA FOR ‘VAULT® ’ (VONOPRAZAN) IN INDIA -- VONOPRAZAN IS A NOVEL GASTROINTESTINAL DRUG AND IS A NEXT GENERATION TREATMENT FOR GASTRO DUODENAL ULCER AND GERD

GLOBAL HEALTH: CO SAYS PARTICIPATED IN E-AUCTION TENDER OF LAND ISSUED BY MUMBAI HOUSING AUTHORITY -- OFFERED 1.25B RUPEES FOR LAND

GLENMARK PHARMACEUTICALS: CO RECEIVES ANDA APPROVAL FOR TOPIRAMATE CAPSULES USP, 15 MG AND 25 MG -- ACCORDING TO IQVIA SALES DATA FOR THE 12-MONTH PERIOD ENDING MAY 2024, THE TOPAMAX® CAPSULES, 15 MG AND 25 MG MARKET3 ACHIEVED ANNUAL SALES OF APPROXIMATELY $21.9M

CIPLA: CO DISCLOSES ADDITIONAL TAX DEMAND OF RS 773.44 CRORE

ASTER DM HEALTHCARE: CO SAYS GOT COMPLAINTS ON ALLEGED UNETHICAL PRACTICES BY SOME EMPLOYEES ; CO TO INITIATE FORENSIC PROBE ON ALLEGED UNETHICAL PRACTICES -- CO SAYS GRANT THORNTON BHARAT TO INITIATE FORENSIC PROBE; ALLEGATIONS PERTAIN TO ASTER HOSPITALS LOCATED IN MEDCITY, KANNUR AND CALICUT

UNICHEM LAB: CO WILL PROVIDE THE NECESSARY RESPONSE WITH IN STIPULATED 15 WORKING DAYS

UNICHEM LAB: CO SAYS AT GOA PLANT THE USFDA INSPECTION CLOSED WITH FIVE OBSERVATIONS WHICH WERE MORE OF PROCEDURAL CHANGES WITH NONE OF THESE RELATED TO DATA INTEGRITY

SUN PHARMA: BOARD MEETING ON AUG 1 TO CONSIDER Q1 RESULTS

LUPIN: CO DIVESTS U.S. COMMERCIAL WOMEN’S HEALTH SPECIALTY BUSINESS TO EVOFEM, INCLUDING SOLOSEC -- TOTAL CONSIDERATION OF UP TO USD 84M

GRANULES INDIA: CO TO CONSIDER Q1 RESULTS ON JULY 30

CIPLA LTD: RS. 62.28 CRORES NSE BLOCK TRADE; FOR ~ 408027 SHARES, AT RS. 1526.25

NARAYANA HRUDAYALAYA LTD: RS. 116.80 CRORES NSE BLOCK TRADE; FOR ~ 960535 SHARES, AT RS. 1216.00

DIVIS LABORATORIES LTD: Rs. 47.64 Crores NSE Block Trade; for ~ 104435 Shares, at Rs. 4562.05

ERIS LIFESCIENCES LTD: RS. 201.02 CRORES NSE BLOCK TRADE; FOR ~ 2001913 SHARES, AT RS. 1004.15

LUPIN: CO GETS USFDA NOD FOR GENERIC MEDICATION-- CO HAS RECEIVED APPROVAL FROM THE USFDA TO MARKET TOPIRAMATE EXTENDED-RELEASE CAPSULES IN THE US, THE DRUG FIRM SAID IN A STATEMENT

ALEMBIC PHARMA: CO RECEIVED ANDA APPROVAL FOR BLOOD-PRESSURE DRUG

PIRAMAL PHARMA: CO SAYS THE INSPECTION AT PPDS AHMEDABAD FACILITY WAS COMPLETED SUCCESSFULLY WITH ZERO FORM - 483 OBSERVATIONS AND NO ACTION INDICATED (NAI) DESIGNATION

ALEMBIC PHARMACEUTICALS: CO ANNOUNCES USFDA TENTATIVE APPROVAL FOR SELEXIPAG FOR INJECTION, 1,800 MCG/VIAL

LUPIN: CO RECEIVES EIR FROM U.S. FDA FOR ITS DABHASA FACILITY -- INSPECTION CONCLUDED WITH NO OBSERVATIONS; FACILITY RECEIVING INSPECTION CLASSIFICATION OF NO ACTION INDICATED

ALKEM LABS: Rs 29.44cr NSE Block Trade; for ~56530 shares, at Rs 5207.15

JB CHEMICALS & PHARMACEUTICALS LTD: Rs. 20.94 Crores NSE Block Trade; for ~ 121498 Shares, at Rs. 1723.40

LAURUS LABS LTD: Rs. 38.13 Crores NSE Block Trade; for ~ 810731 Shares, at Rs. 470.35

NARAYANA HRUDAYALAYA LTD: RS. 62.81 CRORES NSE BLOCK TRADE; FOR ~ 506119 SHARES, AT RS. 1240.95

SHALBY: CO GETS LEASE ORDER ON IMMOVEABLE PROPERTY OF TRUST ASHA PAREKH HOSPITAL FOR 30 YEARS -- CO TO EXPAND ITS HORIZON IN SANTACRUZ, MUMBAI BY CONSTRUCTING NEW HEALTHCARE FACILITY OF 175+ BEDDED

GLENMARK PHARMA: CO AND GLEN SALDANHA TO SELL UP TO 7.85% STAKE VIA OFS -- FLOOR PRICE FOR OFS SET AT RS 810/SHARE -- OFS TO OPEN FOR NON-RETAIL INVESTORS ON JULY 11, AND ON JULY 12 FOR RETAIL INVESTORS

GLENMARK PHARMA: CO TO SELL UP TO 7.84% STAKE OF GLENMARK LIFE SCIENCES

ZYDUS LIFE: CO RECEIVES TENTATIVE APPROVAL FROM USFDA FOR DIROXIMEL FUMARATE DELAYED-RELEASE CAPSULES -- CAPSULES HAS US SALES OF 847M USD

ZYDUS: CO RECEIVES FINAL APPROVAL FROM USFDA FOR SACUBITRIL AND VALSARTAN TABLETS -- TABLETS HAS US SALES HAS US SALES OF APPROX 5.5B USD

MANKIND PHARMA: RS 730.69CR NSE BLOCK TRADE; FOR ~3509576 SHARES, AT RS 2082 (MULTIPLE BLOCKS) (PRE-OPEN)

SHALBY: CO SAYS FUTURE CAPEX WILL BE INCURRED FOR THE CAPACITY EXPANSION OF 130 BEDS TO 200 BEDS IN THE COMING YEAR FROM THE SANAR PROSPECT - CONCALL UPDATE

SHALBY: CO EXPECTS TO REACH BREAKEVEN AT EBITDA LEVEL NEXT QUARTER ONWARDS -- CO EXPECTS TO REACH OVERALL BREAKEVEN BY THE END OF THIS FINANCIAL YEAR OR EARLY NEXT FINANCIAL QUARTER - CONCALL UPDATE

MANKIND PHARMA: BLOCK DEAL ALERT - HEMA CIPEF PLANS TO SELL 37 LAC SHARES VIA BLOCK DEAL (0.9% EQUITY) -- FLOOR PRICE AT 2061 PER SHARE, 2% DISCOUNT -- DEAL LIKELY IN BLOCK WINDOW FOR RS 762 CRS -- IIFL BROKER TO DEAL - CNBC AWAAZ, CITING SOURCES

LUPIN: CO IN AUSTRALIA, ANTICIPATES MARKET EROSION IN TOP PRODUCTS DUE TO NEW ENTRANTS - ANNUAL REPORT

LUPIN: CO SAYS FY25 GROWTH IN BRAZIL TO BE DRIVEN BY PRICE HIKES, PERFORMANCE OF KEY PRODUCTS - ANNUAL REPORT

AARTI DRUGS: CO SAYS N-198 UNIT AT TARAPUR IN WHICH THE FIRE HAS OCCURRED IS OPERATIONAL AGAIN -- CO SAYS THERE HAS BEEN NO MATERIAL IMPACT ON THE FINANCIALS AND OPERATIONS OF BUSINESS

KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO ANNOUNCES ACQUISITION OF 200-BED MULTI-SPECIALTY HOSPITAL AT A PRIME LOCATION IN VIZAG CURRENTLY OPERATING UNDER THE BRAND NAME OF ‘QUEENS NRI HOSPITAL’, THROUGH PURCHASE OF 100% STAKE IN M/S. CHALASANI HOSPITALS PVT LTD, OWNER OF THE HOSPITAL

SHILPA MEDICARE: CO SAYS UNIT 2, RAICHUR CLEARED ANVISA-BRAZIL GMP INSPECTION

ALEMBIC PHARMACEUTICALS: CO ANNOUNCES USFDA FINAL APPROVAL FOR BROMFENAC OPHTHALMIC SOLUTION -- SOLUTION HAS AN ESTIMATED MARKET SIZE OF 168M USD

METROPOLIS HEALTHCARE: COS B2C REVENUES GREW AT 18% YOY FOR Q1FY25

METROPOLIS HEALTHCARE: CO IS DEBT FREE & HAVING CASH RESERVES OF RUPEES 140 CRORES AS ON JUNE 30, 2024

METROPOLIS HEALTHCARE: COS REVENUES GREW BY 13% FOR Q1FY25 ON YOY BASIS

SHRIRAM AMC: CO LISTS LIQUIDSHRI ETF, BOLSTERING SHRIRAM AMC 2.0 GROWTH STRATEGY

VIJAYA DIAGNOSTIC CENTRE LTD: RS. 175.48 CRORES NSE BLOCK TRADE; FOR ~ 2241183 SHARES, AT RS. 783.00

MANKIND PHARMA LTD: Rs. 21.89 Crores NSE Block Trade; for ~ 102796 Shares, at Rs. 2129.85

DR LAL PATHLABS LTD: Rs. 15.07 Crores NSE Block Trade; for ~ 51036 Shares, at Rs. 2953.30

SUN PHARMA: CO EXPECTS HIGH SINGLE-DIGIT CONSOLIDATED TOPLINE GROWTH FOR FY25 -- CO SAYS EXPECT TO START ENROLLING PATIENTS FOR PHASE-2 TRIALS OF WEIGHT LOSS DRUG GLP-1R DURING H2CY24 - ANNUAL REPORT

SANOFI: BOARD MEETING ON JULY 26 TO CONSIDER Q1 RESULTS

SHALBY: Q1 EBITDA MARGIN 16.21% VS 18.32% (YOY)

SHALBY: Q1 REVENUE 2.8B RUPEES VS 2.35B (YOY)

SHALBY: Q1 CONS NET PROFIT 166M RUPEES VS 208M (YOY)

POLY MEDICURE LTD: RS. 95.38 CRORES NSE BLOCK TRADE; FOR ~ 452389 SHARES, AT RS. 2108.45

SHILPA MEDICARE: CO SAYS EXPECT ORDER FOR 5M TABLETS BEFORE JUNE 2025 & 15M BEFORE DEC 2025 - CNBCTV18

APOLLO HOSPITALS: CO TO ACQUIRE 35,12,107 EQUITY SHARES OF AHLL FOR RUPEES 103 CR VIA RIGHTS ISSUE, ENHANCING AHLLS BUSINESS OPERATIONS, WORKING CAPITAL, AND EXPANSION IN HEALTHCARE SERVICES

TORRENT PHARMA: BOARD MEETING ON JULY 23 TO CONSIDER Q1 RESULTS

GLENMARK LIFE SCIENCES: CO SAYS RESTRICTION WAIVED TO FACILITATE COMPLIANCE WITH MINIMUM PUBLIC SHAREHOLDING REQUIREMENTS

GLENMARK LIFE SCIENCES: CO ENTERED INTO A LETTER AGREEMENT WITH GLENMARK PHARMACEUTICALS AND NIRMA; AGREEMENT AMENDS EARLIER SHARE PURCHASE AGREEMENT -- AGREEMENT HAS WAIVED CONTRACTUAL RESTRICTION IMPOSED ON SELLER; IF SELLER IS NOT ABLE TO COMPLETE SALE OF SHAREHOLDING, RESTRICTIONS SHALL BE REINSTATED

SHILPA MEDICARE: SHILPAS CDMO CUSTOMER REPORTED POSITIVE RESULTS FROM PIVOTAL CLINICAL TRIAL -- UNICYCIVE ENTERS MANUFACTURING, SUPPLY AGREEMENT WITH CO; SML EXPECTED TO GET $10M AS MILESTONE INCOME

CIPLA: CO SAYS DISSOLUTION OF WHOLLY OWNED STEP-DOWN SUBSIDIARY IN PHILIPPINES

ZYDUS LIFESCIENCES: CO RECEIVES TENTATIVE APPROVAL FROM US FDA FOR AZILSARTAN MEDOXOMIL TABLETS -- TABLETS HAS AN ANNUAL SALES OF 89M USD

SUN PHARMA: CO SAYS VALIDATION OF NIDLEGY MARKETING AUTHORIZATION APPLICATION SUBMISSION BY EMA

ALEMBIC PHARMACEUTICALS: CO RECEIVES USFDA TENTATIVE APPROVAL FOR IVOSIDENIB TABLETS 250 MG -- US SALES USD 114M

FORTIS HEALTHCARE LTD: Rs. 18.13 Crores NSE Block Trade; for ~ 380218 Shares, at Rs. 476.85

FORTIS HEALTHCARE LTD: Rs. 47.99 Crores NSE Block Trade; for ~ 1005298 Shares, at Rs. 477.35

SANOFI INDIA LTD: Rs. 33.96 Crores NSE Block Trade; for ~ 51103 Shares, at Rs. 6646.00

SYNGENE INTERNATIONAL LTD: Rs. 29.49 Crores NSE Block Trade; for ~ 410331 Shares, at Rs. 718.70

ALEMBIC PHARMACEUTICALS: CO HAS CUMULATIVE TOTAL OF 206 ANDA APPROVALS FROM US FDA

ALEMBIC PHARMACEUTICALS: CO RECEIVED 11 USFDA PRODUCT APPROVALS (FINAL & TENTATIVE) DURING THE QUARTER ENDED 30TH JUNE, 2024

ASTRAZENECA PHARMA: CO APPOINTS MR. SRIKANTH B.S. AS SITE LEAD, INDIA OPERATIONS -- PREVIOUSLY WORKED AT DR. REDDY’S

FORTIS HEALTHCARE LTD: Rs. 19.89 Crores NSE Block Trade; for ~ 423283 Shares, at Rs. 470.00

DIVIS LABORATORIES LTD: Rs. 41.63 Crores NSE Block Trade; for ~ 91175 Shares, at Rs. 4565.95

FORTIS HEALTHCARE LTD: Rs. 46.17 Crores NSE Block Trade; for ~ 1005773 Shares, at Rs. 459.05

DIVIS LABORATORIES LTD: Rs. 28.18 Crores NSE Block Trade; for ~ 61516 Shares, at Rs. 4580.40

THYROCARE TECHNOLOGIES: CO SAYS EXECUTION OF BUSINESS TRANSFER AGREEMENT WITH POLO LABS -- CO WOULD BE ACQUIRING POLOS DIAGNOSTIC, PATHOLOGICAL SERVICES BUSINESS; DEAL FOR 42.6M RUPEES

SOLARA ACTIVE PHARMA SCIENCES: CO SAYS TPG GROWTH IV SF CUT STAKE IN CO TO 4.44% FROM 8.60% -- CUT STAKE VIA OPEN MARKET SALE

HEALTHCARE GLOBAL ENTERPRISES: CO SAYS COST OF ACQUISITION OF 51% STAKE AT 2.08B RUPEES -- COST OF ACQUISITION OF ADDITIONAL 34% STAKE AT 1.55B RUPEES

HEALTHCARE GLOBAL ENTERPRISES: CO SAYS ACQUISITION OF SHARES OF VIZAG HOSPITAL AND CANCER RESEARCH CENTRE

MAX HEALTHCARE INSTITUTE: CO SAYS CONSTRUCTION OF 300 BEDDED HOSPITAL COMPLETED

MAX HEALTHCARE: CO COMMENCES OPERATIONS OF MAX SUPER SPECIALITY HOSPITAL, DWARKA

MAX HEALTHCARE INSTITUTE LTD: RS. 92.07 CRORES NSE BLOCK TRADE; FOR ~ 1004614 SHARES, AT RS. 916.50

MARKSANS PHARMA: CO UNIT RECEIVES RELONCHEM MARKETING AUTHORIZATION FROM UK MHRA FOR 2 TABLETS

GLOBAL HEALTH LTD: Rs. 26.00 Crores NSE Block Trade; for ~ 203487 Shares, at Rs. 1277.95

NEULAND LAB: CO HAS TRANSFERRED A PART OF PROPERTY SITUATED AT HYDERABAD BY WAY OF PERPETUAL LEASE, FOR A CONSIDERATION OF RS. 31.50 CR

ZYDUS LIFESCIENCES: CO UNIT GOT RECTIFICATION ORDER DROPPING DEMAND OF 2.85B RUPEES

IOL CHEMICAL: CHINA’S DRUG REGULATORY AUTHORITY HAS APPROVED THE PRODUCT “FENOFIBRATE” MANUFACTURED BY THE CO -- THIS WILL ENABLE THE CO TO EXPORT ITS FENOFIBRATE API IN CHINA MARKET

LUPIN: CO COMPLETES TRANSFER OF TRADE GENERICS BUSINESS TO UNIT LUPIN LIFE SCIENCES

DIVIS LABORATORIES LTD: Rs. 22.95 Crores NSE Block Trade; for ~ 50062 Shares, at Rs. 4583.55

AUROBINDO PHARMA LTD: Rs. 28.99 Crores NSE Block Trade; for ~ 238113 Shares, at Rs. 1217.50

TORRENT PHARMACEUTICALS LTD: Rs. 24.43 Crores NSE Block Trade; for ~ 87150 Shares, at Rs. 2802.95

ALEMBIC PHARMA: CO RECEIVED US FOOD & DRUG ADMINISTRATION (USFDA) TENTATIVE APPROVAL FOR BOSUTINIB TABLETS -- US SALES OF 275M USD

BLUE JET HEALTHCARE: CO EXPANDS PRODUCTION CAPACITY WITH NEW PHARMA INTERMEDIATES BLOCK IN MAHARASHTRA, -- ADDS 120 KL TO EXISTING 1020.90 KL CAPACITY WITH INVESTMENT OF RUPEES 90 CR

LAURUS LAB: COMPANY HAS RECEIVED THE ESTABLISHMENT INSPECTION REPORT (EIR), INDICATING CLOSURE OF THE INSPECTION

POLY MEDICURE: CO HAS CONSIDERED AND APPROVED RAISING OF FUNDS NOT EXCEECLING RUPEES 1,000 CRORE BY WAY OF QIP

AUROBINDO PHARMA: CO UNIT ACQUIRED ENTIRE SHARE CAPITAL OF ACE LABORATORIES LIMITED, UK -- COST OF ACQUISITION 179.1M RUPEES

ZYDUS LIFESCIENCES: DR. REDDY’S WILL MARKET IT UNDER THE BRAND NAME WOMAB -- CO TO GET UPFRONT LICENSING INCOME, ELIGIBLE TO RECEIVE MILESTONE INCOME BASED ON ACHIEVEMENT OF MILESTONES

ZYDUS LIFESCIENCES: ZYDUS AND DR. REDDYS ANNOUNCE LICENSING AGREEMENT FOR CO-MARKETING OF PERTUZUMAB BIOSIMILAR -- PRODUCT WILL BE MARKETED BY ZYDUS UNDER THE BRAND NAME SIGRIMA

WOCKHARDT: CO SAYS SUCCESSFUL USE OF INVESTIGATIONAL ANTIBIOTIC, ZAYNICH TO TREAT CANCER PATIENT IN U.S. WITH CHRONIC BILATERAL THIGH INFECTION

ORCHID PHARMA: CO PARTNERS WITH CIPLA TO LAUNCH ANTIBIOTIC CEFEPIME-ENMETAZOBACTAM IN INDIA -- ALLIANCE AIMS TO DEPLOY ORCHIDS NOVEL ANTI-INFECTIVE INVENTED IN INDIA

WOCKHARDT: CO CHAIRMAN SAYS WILL LAUNCH ZAYNICH IN INDIA EARLY NEXT YEAR - BBG

HEALTHCARE GLOBAL: VIZAG HOSPITAL, OWNS AND OPERATES A COMPREHENSIVE CANCER CARE HOSPITAL IN THE CITY OF VISHAKHAPATNAM, ANDHRA PRADESH, WITH A WELL-BUILT HOSPITAL INFRASTRUCTURE, HAVING 196 OPERATIONAL BEDS FACILITY

HEALTHCARE GLOBAL: CO HAS AGREED UNDER THE PROVISIONS OF THE SPA TO ACQUIRE 51% (FIFTY-ONE PERCENT) OF THE EQUITY SHARE CAPITAL IN VIZAG HOSPITAL

SUNPHARMA: INDIA EYES INCENTIVES FOR LOCAL OBESITY DRUG PRODUCTION IN 2026 -- CO RACES TO DEVELOP ITS OBESITY DRUG AMID GLOBAL CRUNCH - BBG

ALEMBIC PHARMA: CO RECEIVES USFDA FINAL APPROVAL FOR DOXYCYCLINE CAPSULES -- CAPSULES HAS US SALES OF 123M USD

CIPLA LTD: Rs. 30.91 Crores NSE Block Trade; for ~ 208369 Shares, at Rs. 1483.20

KIMS: CO CONSIDERED AND APPROVED THE PROPOSAL FOR THE SUB-DIVISION OF 1 EQUITY SHARE INTO 5 (FIVE)

NARAYANA HRUDAYALAYA LTD: Rs. 26.30 Crores NSE Block Trade; for ~ 218015 Shares, at Rs. 1206.35

LUPIN: CO SAYS EUROPEAN COURT DISMISSED FINAL APPEAL BY CO AGAINST ORDER OF EUROPEAN COMMISSION LEVYING FINE OF EURO 40M

DISHMAN CARBOGEN AMCIS: CO UNIT COMPLETED US FDA INSPECTION OF MANUFACTURING SITES LOCATED IN HUNZENSCHWIL AND AARAU, IN SWITZERLAND -- CO SAYS INSPECTIONS AT BOTH SITES WERE CONCLUDED WITH NO FORM 483 AND CLASSIFIED AS NO ACTION INDICATED

BIOCON: CO IN INVESTOR PRESENTATION SAYS - FY25 GUIDANCE REVENUE GROWTH IN HIGH SINGLE DIGITS TO LOW DOUBLE DIGITS; OPERATING EBITDA MARGINS COMPARABLE TO FY24; SINGLE DIGIT PAT GROWTH -- BIOSIMILARS ARE AN ATTRACTIVE MARKET WITH THE GLOBAL BIOSIMILAR MARKET EXPECTED TO REACH $56B BY 2030

UNICHEM LABORATORIES: CO SAYS COURT OF JUSTICE OF EU UPHELD FINE OF EURO 13.96M (APPROXIMATELY RS 125.62 CRS) ON CO, ITS UNIT NICHE GENERICS -- FINE PERTAINING TO PATENT DISPUTE SETTLEMENT AGREEMENT DONE FOR PERINDOPRIL DRUG MATTER

AUROBINDO PHARMA: CO UNIT HAS RECEIVED ESTABLISHMENT INSPECTION REPORT CLASSIFYING THE FACILITY AS "VOLUNTARY ACTION INDICATED"

GLOBAL HEALTH LTD: Rs. 38.60 Crores NSE Block Trade; for ~ 295438 Shares, at Rs. 1306.60

DR REDDYS LAB: CO UNIT ENTERED INTO A DEFINITIVE AGREEMENT WITH HALEON PLC AND ITS ASSOCIATE COMPANIES -- UNIT TO ACQUIRE NICOTINELL AND RELATED BRANDS -- SA WILL PAY UPFRONT CASH CONSIDERATION OF GBP 458 MILLION

PIRAMAL PHARMA LTD: RS. 63.89 CRORES NSE BLOCK TRADE; FOR ~ 4112658 SHARES, AT RS. 155.36

VIJAYA DIAGNOSTIC CENTRE: MEDINOVA DIAGNOSTIC SERVICES & CO APPROVED SCHEME OF AMALGAMATION

NEULAND LAB: Rs 96.2cr BSE Block Trade; for ~130000 shares, at Rs 7400 (PRE-OPEN BLOCK)

SHILPA MEDICARE: USFDA HAS CONCLUDED THAT THE INSPECTION HAS NOW BEEN CLOSED WITH THE ISSUANCE OF THE ESTABLISHMENT INSPECTION REPORT (EIR) -- THE FACILITY IS CLASSIFIED AS “NO ACTION INDICATED

JUBILANT PHARMOVA: CO INFORMS REGARDING VOLUNTARY PREPAYMENT OF USD 75 MILLION TERM LOAN, EQUIVALENT TO RS. 626 CR BY SUBSIDIARY CO IN U.S

ALKEM LABS: CO SAYS CLOSURE OF US FDA INSPECTION AT COS MANUFACTURING FACILITY LOCATED AT BADDI -- INSPECTION HAS BEEN CLASSIFIED AS VOLUNTARY ACTION INDICATED AND HAS BEEN CLOSED ACCORDINGLY

FORTIS HEALTHCARE LTD: RS. 73.13 CRORES NSE BLOCK TRADE; FOR ~ 1505498 SHARES, AT RS. 485.75

CIPLA: CO SAYS USFDA VOLUNTARY ACTION INDICATED FOR PATALGANGA FACILITY

GLENMARK PHARMA: GLENMARK PHARMACEUTICALS INC., USA ISSUES VOLUNTARY NATIONWIDE RECALL FOR POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES, USP (750 MG) 10 MEQ K DUE TO FAILED DISSOLUTION - RTRS

KRISHNA INSTITUTE OF MEDICAL SCIENCES: BOARD MEETING ON JUNE 28 TO CONSIDER SUB-DIVISION/SPLIT OF SHARES IN 1:5 RATIO

SHALBY: CO TERMINATED FRANCHISE AGREEMENT WITH MADHUBAN ORTHOPEDIC AND MULTISPECIALTY SURGICAL HOSPITAL

SUN PHARMA: CO SAYS COMBINED ENTITY IS BETTER POSITIONED TO COMPETE IN INCREASINGLY COMPETITIVE GENERICS INDUSTRY

SUN PHARMA: CO SUCCESSFULLY COMPLETED THE MERGER OF TARO PHARMACEUTICAL INDUSTRIES WITH ITS SUBSIDIARY -- TARO IS NOW A PRIVATE COMPANY AND WHOLLY-OWNED BY SUN PHARMA

ASTER DM HEALTHCARE: OLYMPUS CAPITAL ASIA INVESTMENTS CUTS STAKE IN CO BY 9.01% TO HOLD 1.09% STAKE - EXCHANGE FILING

CIPLA: CO SAYS USFDA HAS CONDUCTED AN INSPECTION AT THE CO’S MANUFACTURING FACILITY IN GOA -- CO SAYS ON CONCLUSION OF THE INSPECTION, CO RECEIVED 6 INSPECTIONAL OBSERVATIONS IN FORM 483

DIVIS LABORATORIES: NSE CIRCULAR - DIVIS LABORATORIES AND TRENT LTD NOT AVAILABLE FOR TRADING IN T+0 ROLLING SETTLEMENT CYCLE ON JUNE 24

BLISS GVS PHARMA: CO GETS ORDER FOR SUSPENSION OF FDA LICENSE ISSUED TO COS TABLET DIVISION OF MANUFACTURING UNIT AT PALGHAR (WEST) -- ORDER FOR SUSPENSION OF FDA LICENSE FOR 5 DAYS IN AUGUST 2024

ASTRAZENECA PHARMA: CO WILL NOW EXPLORE A BUYER FOR ITS MANUFACTURING SITE AND EXIT IN DUE COURSE

ASTRAZENECA PHARMA: CO COMPLETED EXPLORATION PHASE FOR SEARCH OF BUYER WHO COULD ACT AS CONTRACT MANUFACTURING ORGANISATION

POLY MEDICURE LTD: RS. 451.13 CRORES NSE BLOCK TRADE; FOR ~ 2293906 SHARES, AT RS. 1966.65

ASTER DM HEALTHCARE: RS 1556.07CR BSE BLOCK TRADE; FOR ~45077282 SHARES, AT RS 345.2

SUN PHARMA: CO SIGNS NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDA FOR INTRODUCING NOVEL GASTROINTESTINAL DRUG, VOLTAPRAZ (VONOPRAZAN) IN INDIA

ASTER DM HEALTHCARE: OLYMPUS CAPITAL ASIA INVESTMENT LIKELY TO SELL 10.1% EQUITY IN ASTER DM TOMORROW -- THE BLOCK INCLUDES A BASE SIZE OF 5.05% WITH AN UPSIZE OPTION OF 10.1% -- FLOOR PRICE AT 331 RUPEES/SH (7.1% DISCOUNT TO CMP) -- DEAL SIZE OF THE BLOCK IS 835 CRORE RUPEES, UPSIZE AT 1,670 CRORE RUPEES - CNBCTV18, CITING SOURCES

SUN PHARMA: CO SAYS DADRA FACILITY RECEIVES WARNING LETTER FROM US FDA -- CO SAYS WARNING LETTER SUMMARIZES VIOLATIONS WITH RESPECT TO CURRENT GOOD MANUFACTURING PRACTICE REGULATIONS

ADVANCED ENZYME TECHNOLOGIES LTD: RS. 420.60 CRORES BSE BLOCK TRADE; FOR ~ 10924787 SHARES, AT RS. 385 (INSTITUTIONAL BLOCK)

ADVANCED ENZYME TECHNOLOGIES LTD: RS. 420.60 CRORES BSE BLOCK TRADE; FOR ~ 10924787 SHARES, AT RS. 385.00

DR REDDYS LABORATORIES LTD: Rs. 16.00 Crores NSE Block Trade; for ~ 26993 Shares, at Rs. 5928.00

GLAND PHARMA: RS 844.78CR BSE BLOCK TRADE; FOR ~4769957 SHARES, AT RS 1771.05

GLAND PHARMA: RS 178.76CR BSE BLOCK TRADE; FOR ~1009334 SHARES, AT RS 1771.05

ZYDUS LIFESCIENCES: ZYNEXT VENTURES, THE VC ARM OF ZYDUS LIFESCIENCES, ANNOUNCES INVESTMENT IN PROMAXO: PIONEERING POINT-OF-CARE MEDICAL IMAGING AND INTERVENTIONS WITH NEXT GENERATION MRI SYSTEMS

AMI ORGANICS: CO SAYS APPROVED FLOOR PRICE FOR QUALIFIED INSTITUTIONS PLACEMENT OF SHARES AT 1228.71 RUPEES PER SHARE

GLAND PHARMA: FOSUN PHARMA INDUSTRIAL PTE LIKELY TO SELL UP TO 8.2M SHARES (5% EQ) OF GLAND PHARMA -- FLOOR PRICE AT 1750 RUPEES/SH (AT A DISCOUNT OF 4.9% TO CMP) -- OFFER SIZE OF THE DEAL IS $172M -- THERE IS LOCK IN PERIOD OF 90 DAYS ON THE SELLER - CNBCTV18, CITING SOURCES

JUBILANT PHARMOVA: CO SAYS USFDA HAS ISSUED 15 OBSERVATIONS PURSUANT TO THE COMPLETION OF AUDIT AT MANUFACTURING FACILITY AT MONTREAL, CANADA

CIPLA: CO EU TO INVEST AN ADDITIONAL EUR 3 MILLION IN ETHRIS

ALEMBIC PHARMACEUTICALS: CO RECEIVES USFDA FINAL APPROVAL FOR DABIGATRAN ETEXILATE CAPSULES AND TENTATIVE APPROVAL FOR DABIGATRAN ETEXILATE CAPSULES

ALKEM LAB: RS 991.21CR BSE BLOCK TRADE; FOR ~2000017 SHARES, AT RS 4956

JUBILANT PHARMOVA: CO SAYS INVESTMENT WILL EXPAND COS PET RADIOPHARMACY NETWORK TO NINE SITES, OVERALL RADIOPHARMACY NETWORK TO FIFTY TWO SITES

JUBILANT PHARMOVA: CO UNIT ANNOUNCED AN INVESTMENT OF $50M TO EXPAND ITS PET RADIOPHARMACY NETWORK -- CO SAYS ADDING SIX PET RADIOPHARMACIES IN STRATEGIC LOCATIONS THROUGHOUT UNITED STATES

JUBILANT PHARMOVA: CO UNIT ISSUED A NOTICE TO ITS LENDERS TO VOLUNTARY PREPAY $75 MILLION TERM LOAN, EQUIVALENT TO 6.26 BLN RUPEES

SUPRIYA LIFESCIENCE: CO SAYS RAJEEV KUMAR JAIN WILL CEASE TO BE CHIEF EXECUTIVE OFFICER

SUN PHARMA: CO INFORMS ABOUT ORAL PRESENTATION AT EULAR 2024 OF DATA FROM GLOBAL PHASE 2B CLINICAL TRIAL DEMONSTRATES DURABILITY OF PAIN RELIEF AFTER A SINGLE INJECTION OF MM-II IN PATIENTS WITH PAINFUL KNEE OSTEOARTHRITIS (OA)

ZYDUS LIFESCIENCES: CO RECEIVES TENTATIVE APPROVAL FROM USFDA FOR AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE TABLETS -- TABLETS HAS US SALES OF 78M USD

LUPIN: USFDA ISSUES FORM 483 WITH ZERO OBSERVATION TO ITS NAGPUR UNIT

SUVEN PHARMACEUTICALS: CO EXECUTED DEFINITIVE AGREEMENTS FOR ACQUIRING 100% OF SHARES IN SAPALA ORGANICS; DEAL FOR 2.3B RUPEES -- CO AGREED TO INITIALLY ACQUIRE 67.5% BY WAY OF SECONDARY TRANSFER FROM SAPALA ORGANICS EXISTING SHAREHOLDERS

TORRENT PHARMA: CO UPDATES USFDA COMPLETES INSPECTION OF INDRAD, GUJARAT FACILITY WITH FIVE OBSERVATIONS

DR REDDYS LABORATORIES: CO UNIT AND INGENUS PHARMACEUTICALS, LLC HAVE ENTERED INTO LICENSE AGREEMENT -- CO UNIT OBTAINED EXCLUSIVE RIGHTS TO COMMERCIALIZE CYCLOPHOSPHAMIDE INJECTION RTD (500 MG/2.5ML; 1G/5ML; 2G/10ML) IN U.S. -- SALES OF THE SAID INGENUS PRODUCT AS PER THE IQVIA FOR THE PAST 12 MONTHS ENDED MARCH 2024 WAS $51.8M

DR REDDYS LABORATORIES: CO UNIT AND INGENUS PHARMACEUTICALS, LLC HAVE ENTERED INTO LICENSE AGREEMENT -- CO UNIT OBTAINED EXCLUSIVE RIGHTS TO COMMERCIALIZE CYCLOPHOSPHAMIDE INJECTION RTD (500 MG/2.5ML; 1G/5ML; 2G/10ML) IN U.S.

ALKEM LABORATORIES LTD: Rs. 25.90 Crores NSE Block Trade; for ~ 51080 Shares, at Rs. 5071.45

GLENMARK PHARMA: CO RECEIVES ANDA APPROVAL FOR ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES -- CAPSULES HAS ACHIEVED ANNUAL SALES OF APPROXIMATELY USD 259.2M

CIPLA: CO SAYS ADDITIONAL COMMISSIONER OF STATE TAX UPHELD ORDER OF OFFICE OF JOINT COMMISSIONER OF STATE TAXES AGAINST CO -- CO SAYS WILL FILE NECESSARY APPEAL WITH THE HIGHER APPELLATE AUTHORITY IN THIS REGARD

IOL CHEMICALS AND PHARMACEUTICALS: CO SAYS EDQM ISSUED CEP CERTIFICATE FOR “ALLOPURINOL”

IOL CHEMICALS AND PHARMACEUTICALS: CO SAYS EDQM ISSUED CEP CERTIFICATE FOR "PANTOPRAZOLE SODIUM SESQUIHYDRATE" FOR ALTERNATIVE PROCESS (PROCESS - II) -- CO SAYS CERTIFICATION WILL ENABLE CO TO EXPORT PRODUCT IN EUROPEAN AND OTHER CEP ACCEPTING COUNTRIES

BIOCON: CO HAS APPROVED THE APPOINTMENT OF MR MUKESH KAMATH, HEAD - BUSINESS FINANCE R&D, AS THE INTERIM CFO -- MR MUKESH HAS WORKED ON VARIOUS ROLES WITH UNITED BREWERIES

POLY MEDICURE LTD: Rs. 34.54 Crores NSE Block Trade; for ~ 187793 Shares, at Rs. 1839.30

MAX HEALTHCARE INSTITUTE LTD: Rs. 16.74 Crores NSE Block Trade; for ~ 201896 Shares, at Rs. 829.25

GLENMARK: FITCH RATINGS SAYS THEY BELIEVE COS ROBUST GROWTH IN INDIA, OTHER MARKETS WILL IMPROVE ITS PROFITABILITY FROM FY24

GLENMARK PHARMA: FITCH AFFIRMS CO AT BB; OUTLOOK STABLE

JUBILANT PHARMOVA: CO ANNOUNCES COMPLETION OF USFDA AUDIT OF CONTRACT MANUFACTURING FACILITY AT SPOKANE, WASHINGTON -- USFDA HAS ISSUED 3 OBSERVATIONS PURSUANT TO COMPLETION OF AUDIT; CO WILL SUBMIT AN ACTION PLAN ON OBSERVATIONS

LUPIN: CO ENTERS INTO BUSINESS TRANSFER AGREEMENT WITH UNIT LUPIN LIFE SCIENCES TO CARVE OUT OF COS TRADE GENERICS BUSINESS IN INDIA WILL BE EFFECTIVE JULY 1, 2024

DR REDDYS LABORATORIES: CO SAYS WE HAVE BEEN ISSUED A FORM 483 WITH FOUR OBSERVATIONS, WHICH WE WILL ADDRESS WITHIN THE STIPULATED TIMELINE

DR REDDYS LABORATORIES: CO SAYS COMPLETED A GMP INSPECTION AT OUR API MANUFACTURING FACILITY (CTO-6) IN SRIKAKULAM, ANDHRA PRADESH -- CO SAYS THE INSPECTION WAS CONDUCTED FROM MAY 30, 2024 TO JUNE 7, 2024

AMI ORGANICS: CO SAYS UNIT I SITUATED AT SACHIN, SURAT WHICH IS INVOLVED IN MANUFACTURING OF VARIOUS INTERMEDIATES FOR ACTIVE PHARMACEUTICALS INGREDIENTS, HAS UNDERGONE A GOOD MANUFACTURING PRACTICES (GMP) INSPECTION BY PHARMACEUTICAL AND MEDICAL DEVICES AGENCY, JAPAN (PMDA) STARTING JUNE 4, 2024 -- CO SAYS THE INSPECTION HAS CONCLUDED SUCCESSFULLY ON JUNE 7, 2024 WITHOUT ANY CRITICAL/MAJOR OBSERVATION

GLAND PHARMA: CO SAYS SRINIVAS SADU APPOINTED AS EXECUTIVE CHAIRMAN AND CEO OF GLAND PHARMA

MANKIND PHARMA LTD: RS. 250.30 CRS NSE BLOCK TRADE; FOR ~ 1184561 SHARES, AT RS. 2113.00

APOLLO HOSPITALS ENTERPRISE LTD: Rs. 24.80 Crores NSE Block Trade; for ~ 41313 Shares, at Rs. 6003.95

JB CHEMICALS & PHARMACEUTICALS LTD: Rs. 23.60 Crores NSE Block Trade; for ~ 132387 Shares, at Rs. 1782.70

SUN PHARMA: CO TO ACQUIRE 9.6% STAKE IN HEALTHCARE CO HAYSTACKANALYTICS FOR RUPEES 33 CR

JUBILANT PHARMOVA: CO HAS ACQUIRED THE REMAINING STAKE IN O2 UPON SUCCESSFUL COMPLETION OF MILESTONES AND ACCORDINGLY THE ACQUISITION OF 19.89% STAKE IN O2 HAS BEEN COMPLETED

ALKEM LABORATORIES:CO AGREED TO INVEST 300 MLN RUPEES IN SHARES OF HAYSTACKANALYTICS -- PROPOSED INVESTMENT WILL HELP CO TO PARTICIPATE IN GROWING DIAGNOSTIC SPACE

INDOCO REMEDIES: CO RECEIVES TENTATIVE ANDA APPROVAL FROM USFDA FOR CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE TABLETS

ORCHID PHARMA: CO RECEIVES DCGI APPROVAL FOR ITS FIRST INVENTED AND MADE-IN-INDIA ANTIBIOTIC DRUG COMBINATION OF CEFEPIME AND ENMETAZOBACTAM (NCE)

CONCORD BIOTECH: CO SAYS HEALTH PRODUCT REGULATORY AUTHORITY OF IRELAND HAS ISSUED EUGMP CERTIFICATE FOR COS UNIT II AT DHOLKA, AHMEDABAD

UNICHEM LABORATORIES: AXSOME THERAPEUTICS SETTLES SUNOSI® (SOLRIAMFETOL) PATENT LITIGATION WITH UNICHEM LABORATORIES

TORRENT PHARMACEUTICALS: CO ENTERS INTO NON-EXCLUSIVE PATENT LICENSING AGREEMENT WITH TAKEDA PHARMACEUTICALS TO COMMERCIALIZE ITS NOVEL GASTROINTESTINAL DRUG IN INDIA

JUBILANT PHARMOVA: CO UPDATE ON DISPOSAL OF INVESTMENT IN SOFIE BIOSCIENCES BY CO -- CO HAS RECEIVED USD 115.9M AS A PART OF THE CONSIDERATION

GLAND PHARMA LTD: Rs. 17.16 Crores NSE Block Trade; for ~ 93006 Shares, at Rs. 1845.00

JB CHEMICALS & PHARMACEUTICALS LTD: Rs. 22.19 Crores NSE Block Trade; for ~ 126201 Shares, at Rs. 1758.00

LUPIN: CO COMPLETES ACQUISITION OF TWO BRANDS FROM SANOFI IN EUROPE AND CANADA

FORTIS HEALTHCARE LTD: Rs. 21.84 Crores NSE Block Trade; for ~ 501035 Shares, at Rs. 435.95

SHILPA MEDICARE: CO UNIT FILED DRUG MASTER FILE OF RECOMBINANT HUMAN ALBUMIN 20% WITH USFDA

SUNPHARMA: CO SAYS NIDLEGY™ MARKETING AUTHORIZATION APPLICATION SUBMITTED TO EMA

DR REDDYS LABORATORIES: CO UNIT AURIGENE PHARMACEUTICAL SERVICES LTD, A GLOBAL CRDMO, ANNOUNCES THE OPENING OF ITS BIOLOGICS FACILITY OFFERING PROCESS DEVELOPMENT AND CLINICAL SCALE MANUFACTURING CAPABILITIES

BIOCON: CO HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (US FDA), FOR ITS VERTICALLY INTEGRATED, COMPLEX INJECTABLE DRUG PRODUCT, MICAFUNGIN (50MG AND 100MG VIALS), USED AS AN ANTIFUNGAL MEDICATION TO TREAT FUNGAL OR YEAST INFECTIONS

ALKEM LABORATORIES LTD: RS. 102.70 CRORES NSE BLOCK TRADE; FOR ~ 213643 SHARES, AT RS. 4807.30

ADVANCED ENZYME TECHNOLOGIES LTD: Rs. 15.03 Crores NSE Block Trade; for ~ 421070 Shares, at Rs. 356.90

SMS PHARMA: CO SAYS TOP-LINE GROWTH IS EXPECTED TO BE AROUND 20% TO 25% FOR FY25 -- CO SAYS GROSS MARGIN GROWTH IS EXPECTED TO BE AROUND 25% FOR FY 2025 - CONCALL UPDATES

AUROBINDO PHARMA: CO SAYS AGREEMENT FOR EXPLORING POSSIBILITIES TO ENTER INTO CONTRACT MANUFACTURING OPERATIONS FOR BIOLOGICALS -- THERANYM WILL INVEST AROUND 10 BLN RUPEES FOR ESTABLISHING MANUFACTURING FACILITY

AUROBINDO PHARMA: CO SAYS THERANYM BIOLOGICS AND MSD SIGNED A MASTER SERVICE AGREEMENT -- AGREEMENT FOR EXPANSION OF BIOLOGICS MANUFACTURING FACILITIES OF THERANYM

ZYDUS LIFESCIENCES: CO UNIT APPROVED SHARE PURCHASE AGREEMENT FOR ACQUIRING SHARES OF ZYDUS MEDTECH

GRANULES INDIA LTD: RS. 50.39 CRORES NSE BLOCK TRADE; FOR ~ 1200736 SHARES, AT RS. 419.65

SUVEN PHARMACEUTICALS LTD: Rs. 18.60 Crores NSE Block Trade; for ~ 300629 Shares, at Rs. 618.65

GLAND PHARMA LTD: Rs. 20.90 Crores NSE Block Trade; for ~ 112769 Shares, at Rs. 1853.00

IPCA LAB: CO SAYS DOMESTIC BUSINESS EXPECTED TO GROW AROUND 12% - CONCALL UPDATE

IPCA LAB: CO SAYS GUIDANCE FOR FY25: STANDALONE BUSINESS GROWTH OF 10.5% TO 11%, EBITDA MARGINS IMPROVING TO 20.5% TO 21%, CONSOLIDATED BUSINESS GROWTH OF 14% TO 14.25%, AND CONSOLIDATED EBITDA IMPROVING TO 18% - CONCALL UPDATE

GUFIC BIOSCIENCES: CO SAYS REVENUE GROWTH EXPECTED BETWEEN 15% TO 20% YEAR-OVER-YEAR FOR THE NEXT 3 TO 4 YEARS - CONCALL UPDATE

SUVEN PHARMA: CO SAYS GUIDANCE FOR FY 25 IS POSITIVE, WITH MID-TERM TO LONG-TERM GROWTH EXPECTED -- CO EXPECTS TO SEE GROWTH BOTH IN REVENUE AND EBITDA FOR THE FULL YEAR OF 25, WITH GROWTH ACCELERATING IN FY 26 - CONCALL UPDATES

GLENMARK PHARMACEUTICALS: CO IN INVESTOR PRESENTATION SAYS - ESTIMATED TOTAL ANNUAL GLOBAL SALES OF US$ 300 – 400 MILLION OVER THE NEXT FIVE YEARS -- OVERALL CASH BURN FOR IGI WILL REDUCE TO ~US$ 50 MILLION STARTING FY25

DISHMAN CARBOGEN AMCIS: Q4 EBITDA 629M RUPEES VS 510M (YOY) -- Q4 EBITDA MARGIN 9.60% VS 8.26% (YOY)

DISHMAN CARBOGEN AMCIS: Q4 CONS NET LOSS 699M RUPEES VS LOSS 707M (YOY) -- Q4 REVENUE 6.5B RUPEES VS 6.2B (YOY)

KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO ANNOUNCES EXPANSION BY SETTING UP OF 350 BED SUPER SPECIALTY HOSPITAL IN BENGALURU, KARNATAKA -- UNIT ENTERED INTO AGREEMENT WITH PES TO EXCLUSIVELY MANAGE PROPOSED UNDER-CONSTRUCTION HOSPITAL UNIT

KRISHNA INSTITUTE OF MEDICAL SCIENCES: CO UNIT ENTERED INTO A DEFINITIVE AGREEMENTS WITH PEOPLE EDUCATION SOCIETY (PES) -- DEFINITIVE AGREEMENTS TOWARDS LEASE OF LAND AND HOSPITAL BUILDING FOR A PERIOD OF 25 YEARS

SUN PHARMA: CO ACCEPTED PREFERENTIAL OFFER TO ACQUIRE 14.28% SHARES OF INDIAN FOUNDATION FOR QUALITY MANAGEMENT -- COST OF ACQUISITION 125 MLN RUPEES

NATCO PHARMA: CO ANNOUNCES SUBMISSION OF ABBREVIATED NEW DRUG APPLICATION (ANDA) CONTAINING A PARAGRAPH IV CERTIFICATION WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE GENERIC VERSION OF RIMEGEPANT SULFATE TABLET EQ 75MG BASE STRENGTH

LAURUS LABS: WILLOW BIOSCIENCES INC ANNOUNCES MULTI-PRODUCT DEVELOPMENT AND LICENSING PARTNERSHIP WITH LAURUS LABS

SASTASUNDAR VENTURES: Q4 REVENUE 3.07B RUPEES VS 3.13B (YOY)

SASTASUNDAR VENTURES: Q4 CONS NET PROFIT 164.4M RUPEES VS LOSS 342M (YOY)

APOLLO HOSPITALS ENTERPRISE: CO RECOMMENDED A FINAL DIVIDEND OF 10 RUPEES PER EQUITY SHARE

APOLLO HOSPITALS ENTERPRISE: Q4 EBITDA 6.41B RUPEES VS 4.88B (YOY); EST 6.23B -- Q4 EBITDA MARGIN 12.96% VS 11.35% (YOY); EST 12.7%

APOLLO HOSPITALS ENTERPRISE: Q4 REVENUE 49.4B RUPEES VS 43B (YOY); EST 48.86B

APOLLO HOSPITALS ENTERPRISE: Q4 CONS NET PROFIT 2.54B RUPEES VS 1.45B (YOY); EST 2.50B

SUVEN PHARMA: Q4 EBITDA 733.4M RUPEES VS 1.72B (YOY) -- Q4 EBITDA MARGIN 29% VS 46.53% (YOY)

SUVEN PHARMA: Q4 REVENUE 2.53B RUPEES VS 3.7B (YOY)

SUVEN PHARMA: Q4 CONS NET PROFIT 533.7M RUPEES VS 1.24B (YOY)

TARSONS PRODUCTS: Q4 EBITDA 339M RUPEES VS 393M (YOY) -- Q4 EBITDA MARGIN 39.10% VS 47.84% (YOY)

TARSONS PRODUCTS: Q4 REVENUE 866M RUPEES VS 820M (YOY)

TARSONS PRODUCTS: Q4 SL NET PROFIT 188M RUPEES VS 228M (YOY)

ALEMBIC PHARMACEUTICALS: CO RECEIVES USFDA FINAL APPROVAL FOR SACUBITRIL AND VALSARTAN TABLETS -- SACUBITRIL AND VALSARTAN TABLETS HAS US SALES OF 5.3B USD

MARKSANS PHARMA: Q4 EBITDA 1.09B RUPEES VS 1.10B (YOY) -- Q4 EBITDA MARGIN 19.58% VS 22.54% (YOY)

MARKSANS PHARMA: Q4 CONS NET PROFIT 789M RUPEES VS 819M (YOY)

MARKSANS PHARMA: Q4 CONS NET PROFIT 789M RUPEES VS 819M (YOY)

POLY MEDICURE LTD: RS. 59.37 CRORES NSE BLOCK TRADE; FOR ~ 323414 SHARES, AT RS. 1835.70

SOLARA ACTIVE PHARMA: CO WILL HIT ITS HISTORICAL HIGHS OF ITS EBITDA IN THE NEXT 6 QUARTERS TO 8 QUARTERS -- CO EXPECTS CASH GENERATION TO BE GREATER THAN EBITDA, LEADING TO A SIGNIFICANT DEBT REDUCTION FROM OPERATIONS - CONCALL UPDATES

SOLARA ACTIVE PHARMA: CO SAYS GUIDANCE FOR THE YEAR IS A REVENUE GROWTH OF APPROXIMATELY INR1,500 CRORES AND AN EBITDA RUN-RATE OF AROUND INR260 CRORES -- INR290 CRORES - CONCALL UPDATE

ALKEM LAB: CO PROVIDED GUIDANCE FOR FY 25, INCLUDING REVENUE GROWTH OF 7% TO 8% FROM NEW PRODUCT LAUNCHES IN THE US MARKET - CONCALL UPDATE

GUFIC BIOSCIENCES: Q4 EBITDA 342.3M RUPEES VS 321.5M (YOY) -- Q4 EBITDA MARGIN 17.55% VS 18.58% (YOY)

GUFIC BIOSCIENCES: Q4 REVENUE 1.95B RUPEES VS 1.73B (YOY)

GUFIC BIOSCIENCES: Q4 SL NET PROFIT 200M RUPEES VS 181M (YOY)

HEALTHCARE GLOBAL ENTERPRISES: CO HAS EXCEPTIONAL ITEM OF 39M RUPEES

HEALTHCARE GLOBAL ENTERPRISES: Q4 EBITDA 920.3M RUPEES VS 763M (YOY) -- Q4 EBITDA MARGIN 18.66% VS 17.31% (YOY)

HEALTHCARE GLOBAL ENTERPRISES: Q4 REVENUE 4.93B RUPEES VS 4.41B (YOY)

HEALTHCARE GLOBAL ENTERPRISES: Q4 CONS NET PROFIT 212.6M RUPEES VS 84M (YOY)

FDC: Q4 EBITDA 563.2M RUPEES VS 489M (YOY) -- Q4 EBITDA MARGIN 12.19% VS 11.26% (YOY)

FDC: Q4 REVENUE 4.62B RUPEES VS 4.35B (YOY)

FDC: Q4 CONS NET PROFIT 462.8M RUPEES VS 307M (YOY)

SOLARA ACTIVE PHARMA SCIENCES: CO HAS EXCEPTIONAL ITEM OF LOSS 1.22B RUPEES

SOLARA ACTIVE PHARMA SCIENCES: Q4 EBITDA 97.6M RUPEES VS 487.6M (YOY) -- Q4 EBITDA MARGIN 3.26% VS 12.81% (YOY)

SOLARA ACTIVE PHARMA SCIENCES: Q4 REVENUE 2.99B RUPEES VS 3.8B (YOY)

SOLARA ACTIVE PHARMA SCIENCES: Q4 CONS NET LOSS 2.55B RUPEES VS PROFIT 38M (YOY)

JUBILANT PHARMOVA: CO’S WHOLLY OWNED SUBSIDIARY ‘JPL’ PLANS TO SELL ITS 25.8% STAKE IN SOFIE BIOSCIENCES INC. (‘SOFIE’) AT AN AGGREGATE VALUE OF USD 143.27M OR 1200CR RUPEES

JUBILANT PHARMOVA: CO STARTING PHASE II CLINICAL TRIAL TO TREAT ET AND MPN PATIENTS WITH THROMBOCYTOSIS IN H1 2024

JUBILANT PHARMOVA: Q4 EBITDA 2.71B RUPEES VS 2.19B (YOY) -- Q4 EBITDA MARGIN 15.43% VS 13.20% (YOY)